Introduction {#s1}
============

The mammalian blastocyst inner cell mass (ICM) contains undifferentiated, pluripotent cells capable of generating all tissue lineages of the embryo proper. Cultured embryonic stem cells (ESCs) are derived from these cells and have similar capabilities ([@bib1]). The POU transcription factor Oct4/Pou5f1 is an indispensable component of the regulatory circuitry underlying these properties ([@bib23]). It is expressed in the ICM and in ESCs where its loss accompanies differentiation ([@bib25]). Oct4 is also widely used to generate induced pluripotent stem cells (iPSCs) from somatic cells ([@bib38]).

Together with other factors, Oct4 sustains pluripotency by activating 'core' targets such as *Pou5f1* (encoding Oct4 itself) and *Nanog* ([@bib6]). It also maintains 'poised' targets, including developmentally critical transcription regulators, in a silent but readily inducible state ([@bib5]; [@bib21]). These genes frequently encode developmentally important transcription factors and are marked with a bivalent chromatin signature defined by the simultaneous presence of H3K4me3 and H3K27me3 ([@bib2]; [@bib5]; [@bib16]; [@bib28]).

Oct1/Pou2f1 is a widely expressed protein related to Oct4. The two proteins have similar DNA-binding specificity ([@bib41]). In somatic cells, it regulates stem cell and immune memory phenotypes ([@bib20]; [@bib35]) and is associated with cytotoxic stress resistance, glycolytic metabolism and malignant transformation ([@bib4]; [@bib32]; [@bib39]). Oct1 amplification and/or overexpression correlates with tumor aggressiveness in esophageal, gastric, prostate, lung, cervical, and colorectal cancer ([@bib45]). It is also co-expressed with Oct4 in ESCs ([@bib27]; [@bib30]). Oct1-deficient mice undergo implantation but show defects following gastrulation, most prominently in extra-embryonic tissues, where trophoblast stem cell development is arrested and expression of the direct Oct1 target *Cdx2* is defective ([@bib31]). Tetraploid complementation bypasses this developmental restriction, allowing embryos to survive to E8.5--9.5 where they die from an embryo-intrinsic block. These embryos are runted, developmentally arrested, and lack beating hearts. ([@bib31]). A slightly less severe germline allele dies in mid-gestation and manifests runting, anemia, hemorrhaging, and other defects with variable penetrance ([@bib47]).

Here, we show that ESCs lacking Oct1 have no discernable defects when maintained in an undifferentiated state, but that silent, normally poised developmental-specific genes fail to induce properly upon differentiation. Additionally, genes specific for alternative developmental lineages are inappropriately expressed. Most prominently, placenta-specific genes not normally expressed in any ESC-derived lineage are induced, indicating that Oct1 restricts extra-embryonic gene expression in differentiating ESCs. Additionally, these cells show phenotypic defects when differentiated into multiple lineages, form smaller and less differentiated teratomas, and fail to generate chimerism when injected into blastocysts. ChIPseq identifies a group of targets co-bound by Oct1 and Oct4 in ESCs associated with non-classical binding sites termed MOREs ([M]{.ul}ore Palindromic [O]{.ul}ctamer [R]{.ul}elated [E]{.ul}lements, ATGCATATGCAT). These sites are inducibly bound by Oct1 in somatic cells lacking Oct4. The function of Oct1 at these genes is to insulate their expression against repression by oxidative stress, and consistently Oct1-deficient ESCs are hypersensitive to oxidative stress. Oct1 associates with developmentally poised targets upon differentiation and Oct4 loss, explaining the altered gene expression observed with RNAseq. These results establish Oct1 as a key mediator of both developmental-specific gene induction and repression, and identify a dynamic interplay in which Oct1 replaces Oct4 at target genes as ESCs differentiate and early decisions about induction or repression of lineage-specific genes are made.

Results {#s2}
=======

Oct1 germline-deficient ESCs are phenotypically normal but differentiate abnormally {#s2-1}
-----------------------------------------------------------------------------------

We derived Oct1-deficient ESC lines by intercrossing *Pou2f1* germline heterozygotes ([@bib47]). Oct1-deficient animals die in utero ([@bib31]; [@bib47]), but survive long enough to derive ESCs. Two Oct1-deficient lines and two littermate WT controls were generated. All had normal karyotypes (not shown). Oct1-deficient ESCs proliferate at normal rates (not shown), are morphologically normal ([Figure 1A](#fig1){ref-type="fig"}) and can be propagated for a month in culture with no loss of ESC morphology (not shown). They express normal levels of Oct4, Sox2, and Nanog protein but no Oct1 ([Figure 1B](#fig1){ref-type="fig"}). In addition, cells express the pluripotency-associated *Pou5f1* (Oct4), *Sox2*, *Nanog,* and *Dppa4* mRNAs at normal levels ([Figure 1C](#fig1){ref-type="fig"}). *Ahcy*, a stress-inducible Oct1 target in which the function of Oct1 is to prevent stress-associated repression ([@bib13]; [@bib33]), was also unaltered.10.7554/eLife.20937.003Figure 1.Abnormal developmental gene induction in ESCs lacking Oct1.(**A**) Phase microscopy images of four ESC lines (two Oct1 deficient, two WT littermate controls) derived from *Pou2f1^-/+^* intercrosses. Passage 5 ESCs on feeder fibroblasts are shown. (**B**) Immunoblot comparing lysates of a WT control line and littermate Oct1-deficient line. GAPDH is shown as a loading control. (**C**) mRNA expression of six genes in WT control and littermate Oct1-deficient ESC lines. Data were obtained by RT-qPCR using three biological replicates of a single line of each genotype. Error bars denote standard deviations. *p*-values: NS=non-significant, \* \< 0.05, \*\* \< 0.01, \*\*\* \< 0.001. (**D**) Phase microscopy images of 4-day EBs derived from ESCs ±Oct1. Three representative images of each genotype from wells of a 96-well plate are shown. (**E**) EBs were collected at 4, 9, and 14 days, and cDNA was prepared and subjected to RT-qPCR. Expression levels were normalized to GAPDH. Pluripotency genes (*Pou5f1*, *Sox2*) and *Pou2f1* were tested. Three biological replicates were performed. Error bars denote ±standard deviation. (**F**) Additional genes representative of all three germ layers, *Sox17*, *T* ,and *Fgf5*, were tested as in E. (**G**) Three known poised Oct4 target genes, *Hoxa5*, *Hoxc6,* and *Gata2*, were tested as in E.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.003](10.7554/eLife.20937.003)10.7554/eLife.20937.004Figure 1---figure supplement 1.Abnormal morphology in differentiating Oct1-deficient cells manifests by day 5 of EB formation.(**A**) Phase microscopy images of WT and Oct1-deficient ESCs aggregating into EBs. Top: 1 day of culture. Bottom: day 2. (**B**) Day 5. EBs are in low attachment dishes.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.004](10.7554/eLife.20937.004)

To study differentiation, we used early-passage Oct1-deficient and WT control ESCs to form embryoid bodies (EBs). Oct1-deficient ESCs were able to aggregate into EBs at d four with morphology similar to WT ([Figure 1D](#fig1){ref-type="fig"}). Similar results were obtained at days 1 and 2 ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). During EB formation, *Pou5f1* and *Sox2* were down-modulated with similar kinetics in Oct1-deficient and WT cells, while *Pou2f1* (Oct1) remained undetectable ([Figure 1E](#fig1){ref-type="fig"}). *Sox17* (endoderm), *Brachyury* (*T*, definitive mesoderm), and *Fgf5* (definitive ectoderm) expression in Oct1-deficient EBs was grossly similar to WT at some (days 4, 9, or 14) timepoints ([Figure 1F](#fig1){ref-type="fig"}), consistent with findings that Oct1 is dispensable for gastrulation ([@bib31]; [@bib47]). However, there were consistent defects in expression in the Oct1-deficient condition at day 14 for *Sox17* and day 4 for *T* and *Fgf5. Sox17*, *T* and *Fgf5* are known Oct4 targets ([@bib7]). By day 5, Oct1-deficient EBs were somewhat smaller in appearance ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). We therefore looked for further evidence of defects in induction kinetics in three other known silent but developmentally inducible Oct4 target genes: *Hoxa5*, *Hoxc6,* and *Gata2* ([@bib7]). Each of these genes showed a similar pattern of defective induction in Oct1-deficient EBs relative to WT controls ([Figure 1G](#fig1){ref-type="fig"}).

To study gene induction using a more developmentally restricted system, we analyzed expression of known developmentally inducible Oct4 target genes during RA-mediated differentiation of WT and Oct1-deficient ESCs. RA treatment of ESCs ultimately results in a largely neuronal phenotype, but waves of gene expression, differentiation, proliferation, and cell death take place during the course of RA treatment ([@bib46]). Upon differentiation, ESCs ±Oct1 lose their clustered, spherical, refractile morphology with similar kinetics (not shown). *Pou5f1* and *Sox2* were also lost with similar kinetics ±Oct1, while *Pou2f1* was not detectable in KO cells ([Figure 2A](#fig2){ref-type="fig"}). To study developmental gene expression, we tested *Hoxa5*, *Hoxc6*, *Cdx2,* and *Sox17*. These genes encode developmentally important transcription factors and are known Oct4 targets ([@bib7]), but are silent in ESCs. Upon RA-mediated differentiation, lineage-appropriate (ectoderm) genes such as *Hoxa5* and *Hoxc6* ([@bib11]) normally 'resolve' their bivalent state by losing H3K27me3 and becoming induced, while lineage-inappropriate (e.g. endoderm) genes such as *Cdx2* and *Sox17* normally resolve by losing H3K4me3, gaining DNA methylation, and becoming stably silenced. Induction of *Hoxa5* and *Hoxc6* was robust following RA-mediated differentiation of WT cells, but defective in the Oct1 KO condition ([Figure 2B](#fig2){ref-type="fig"}). In contrast, *Cdx2* was ectopically activated upon RA-mediated differentiation of Oct1-deficient ESCs ([Figure 2B](#fig2){ref-type="fig"}). Similarly, the definitive endoderm-specific gene *Sox17* is not normally induced upon RA-mediated differentiation, but showed ectopic expression in the absence of Oct1 ([Figure 2B](#fig2){ref-type="fig"}). The ectopic *Sox17* expression observed with RA differentiation differed from the expression defects observed in Oct1-deficient EBs, which include endodermal lineages and which showed 100-fold stronger *Sox17* expression ([Figure 1F](#fig1){ref-type="fig"}). These results indicate that Oct1-deficient ESCs induce lineage-appropriate developmental genes poorly, while ectopically expressing lineage-inappropriate genes.10.7554/eLife.20937.005Figure 2.Effect of Oct1 loss on RA-mediated differentiation and neurogenesis.(**A**) Quantitative RT-PCR results are shown for *Pou5f1* (Oct4), *Sox2,* and *Pou2f1* (Oct1) mRNA relative to a GAPDH standard. Average of three biological replicates ±standard deviation is shown. (**B**) Similar analysis performed for the Oct4 targets *Hoxa5*, *Hoxc6*, *Cdx2,* and *Sox17*. (**C**) 293 T cells were transiently transfected with a lentiviral vector (pHAGE) expressing mouse Oct1. Lysates were prepared 48 hr later and immunoblotted for Oct1. Un-transfected cells are shown as a negative control (lane 1). Oct1 is not visible in these cells because of the lightness of the exposure. The same cells transduced with a retroviral vector encoding Oct1 (lane 3) are shown as a positive control. β-actin is shown as a loading control. (**D**) Oct1-deficident ESCs were differentiated using RA for 14 days. 4 days into the timecourse, cells were infected with lentiviruses expressing Oct1 and a puromycin resistance cassette, or an empty vector (EV) control. Cells were selected with puromycin for the remainder of the timecourse. cDNAs from the endpoint cultured were used to study expression of *Hoxa5* relative to an RPL13 ribosomal protein internal standard. Cells were prepared in triplicate for each condition. Error bars denote ±standard deviation. \*denotes p\<0.05. (**E**) Immunofluorescence images of WT and Oct1-deficient ESCs differentiated into neurons. Cells were cultured as EBs for 8 days, followed by culture for a further 8 days in neuralizing media (see Materials and methods). β-tubulin III and DAPI staining are shown. (**F**) Quantification of 300--400 cells from three individual differentiation experiments. Error bars denote ±standard deviation. (**G**) Similar to (**E**) except cells were cultured for eight additional d in neuralizing media. (**H**) Similar to (**F**) except using cells cultured for eight additional d. (**I**) 16 d-differentiated neuron cultures of similar genotypes were pooled and subjected to RT-qPCR using primers specific for *Tubb3*, *Nestin,* and *Map2*. Expression was assessed relative to GAPDH. Averages of three biological replicates are shown. Error bars denote ±standard deviation.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.005](10.7554/eLife.20937.005)10.7554/eLife.20937.006Figure 2---figure supplement 1.β-tubulin III staining of neuralizing WT and Oct1-deficient EBs.(**A**) WT cells. (**B**) Oct1-deficient cells. Two day-old EBs were used.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.006](10.7554/eLife.20937.006)

In order to determine whether forced Oct1 expression during differentiation was sufficient to correct defects in gene expression, we differentiated Oct1-deficient ESCs using RA and infected the cell during the differentiation timecourse with lentiviral vectors expressing Oct1 and a puromycin reistance cassette, or empty vectors containing the puromycin resistance cassette alone. We confirmed that cells transduced with this vector overexpressed Oct1 by immunoblotting ([Figure 2C](#fig2){ref-type="fig"}). Cells were infected over 2 consecutive days and selected with puromycin throughout the remained of the 14-day differentiation timecourse. At timepoints after day 6, infection and selection with empty vector skewed the expression of genes such as *Hoxa5*, suggesting that infection and selection were skewing the populations of cells in the culture. Cells infected at 4 and 5 days, however, did not show major differences (not shown), suggesting that the composition of cells in culture was not being significantly altered. We therefore infected differentiating Oct1-deficient cells consecutively on days 4 and 5, prepared cDNAs at day 14 and examined gene expression. By RT-qPCR, Oct1 was undetectable in cells transduced and selected with empty vector but robustly expressed by cells transduced with Oct1 (not shown). Expression of the developmentally-inducible *Hoxa5* gene was significantly augmented (p=0.026) by ectopic Oct1 expression ([Figure 2D](#fig2){ref-type="fig"}). These results indicate that restoration of Oct1 expression at these times and conditions can correct at least some of the gene expression defects associated with Oct1 deficiency.

RA-mediated differentiation yields neuronal precursor cells but not neurons. We used a differentiation system involving EB generation and culture in insulin, transferrin and selenium (see Materials and methods) to generate arborized neurons that express the marker β-tubulin III (*Tubb3*) and the neuroectoderm genes Nestin (*Nes*) and *Map2*. Staining of 2-day-old EBs for β-tubulin III prior to laminin/poly-L-lysine dish attachment -- early in the differentiation protocol - revealed fewer β-tubulin III-positive cells in the Oct1 deficient condition ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Upon complete differentiation (8 d EBs, 8 days in neuralizing monolayer culture), WT ESCs formed neurons robustly ([Figure 2E](#fig2){ref-type="fig"}, asterisk) while few β-tubulin III-expressing neurons were formed from Oct1-deficient ESCs. Oct1-deficient cells that did induce β-tubulin III tended to do so at lower levels, and the few cells that did express β-tubulin III robustly were nevertheless abnormal ([Figure 2E--F](#fig2){ref-type="fig"}, arrow). To test if Oct1 loss induced a kinetic delay that could be overcome by longer culture, cells were incubated for 8 or 16 additional days (16 or 24 days in neuralizing medium, 24 or 32 days total differentiation). In neither case were neurons formed ([Figure 2G--H](#fig2){ref-type="fig"} and data not shown). To study gene expression, individual wells of common genotypes differentiated for 16 days were pooled and subjected to RT-qPCR for *Tubb3*, *Nes* and *Map2*. Each of these genes showed defective expression in the absence of Oct1 ([Figure 2I](#fig2){ref-type="fig"}).

To test an unrelated developmental system, we performed cardiomyocyte differentiation by culturing EBs in hanging drops followed by culture with gelatin (see Materials and methods). Oct1-deficient ESCs failed to form beating cardiomyocytes, unlike WT ([Figure 3A](#fig3){ref-type="fig"} and [Videos 1](#media1){ref-type="other"}--[12](#media12){ref-type="other"}). RNA was collected from pooled beating and non-beating WT colonies, and Oct1-deficient colonies, and used to analyze *Mef2c* and *Hand1*, regulators of cardiomyocyte differentiation, and the terminal differentiation markers *Mlc2v* and *Mlc2a*. We observed *Mlc2v* expression defects in the Oct1-deficient condition equivalent to non-beating cardiomyocyte colonies from WT ESCs. *Mlc2a* and *Mef2c* expression was even weaker than non-beating WT cardiomyocyte colonies ([Figure 3B](#fig3){ref-type="fig"}). In contrast, *Hand1* showed no expression defects ([Figure 3B](#fig3){ref-type="fig"}), indicating that Oct1 deficiency does not globally down-regulate genes associated with cardiomyocyte differentiation. Cumulatively, the results indicate that although Oct1-deficient ESCs appear normal in the absence of differentiation cues, they do not induce poised developmentally inducible genes and fail to repress lineage-inappropriate genes such as *Cdx2* and *Sox17*, resulting in multiple cellular defects following differentiation.10.7554/eLife.20937.007Figure 3.Defective cardiomyocyte differentiation in ESCs lacking Oct1.(**A**) Cardiomyocytes were generated from individual EBs using 24-well dishes with gelatin. Functionality (±beating) was assessed for each well (16 per genotype) and plotted. (**B**) The wells assessed in (**A**) were pooled according to genotype and function (beating WT, non-beating WT and non-beating Oct1 deficient), cDNA was prepared and used for RT-qPCR using primers for *Mlc2v*, *Mlc2a*, *Mef2c* and *Hand1*. Averaged results from three replicates are shown. Error bars denote standard deviation. p-Values: NS=non-significant, \* \< 0.05, \*\* \< 0.01, \*\*\* \< 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.007](10.7554/eLife.20937.007)Video 1.Example WT ESC line cardiomyocyte differentiation 1.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.008](10.7554/eLife.20937.008)10.7554/eLife.20937.008Video 2.Example WT ESC line cardiomyocyte differentiation 2.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.009](10.7554/eLife.20937.009)10.7554/eLife.20937.009Video 3.Example WT ESC line cardiomyocyte differentiation 3.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.010](10.7554/eLife.20937.010)10.7554/eLife.20937.010Video 4.Example WT ESC line cardiomyocyte differentiation 4.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.011](10.7554/eLife.20937.011)10.7554/eLife.20937.011Video 5.Example WT ESC line cardiomyocyte differentiation 5.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.012](10.7554/eLife.20937.012)10.7554/eLife.20937.012Video 6.Example WT ESC line cardiomyocyte differentiation 6.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.013](10.7554/eLife.20937.013)10.7554/eLife.20937.013Video 7.Example WT ESC line cardiomyocyte differentiation 1.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.014](10.7554/eLife.20937.014)10.7554/eLife.20937.014Video 8.Example WT ESC line cardiomyocyte differentiation 2.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.015](10.7554/eLife.20937.015)10.7554/eLife.20937.015Video 9.Example WT ESC line cardiomyocyte differentiation 3.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.016](10.7554/eLife.20937.016)10.7554/eLife.20937.016Video 10.Example WT ESC line cardiomyocyte differentiation 4.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.017](10.7554/eLife.20937.017)10.7554/eLife.20937.017Video 11.Example WT ESC line cardiomyocyte differentiation 5.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.018](10.7554/eLife.20937.018)10.7554/eLife.20937.018Video 12.Example WT ESC line cardiomyocyte differentiation 6.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.019](10.7554/eLife.20937.019)10.7554/eLife.20937.019

Oct1 conditional-deficient ESCs display abnormal gene expression upon differentiation {#s2-2}
-------------------------------------------------------------------------------------

Although the ESC lines described above were derived from littermate animals and had normal karyotypes, it was possible that the developmental phenotypes and altered gene expression patterns resulted from differences unrelated to Oct1 status. Furthermore, the observed gene expression defects could result from compensatory changes due to development in an Oct1-deficient environment. Finally, the allele used to generate these lines is a severe hypomorph rather than a complete null ([@bib47]). To circumvent these issues, we generated tamoxifen-inducible, Oct1 conditional-deficient ESCs.

We previously described *Pou2f1* conditional (floxed) mice ([@bib35]). We generated inducible-conditional Oct1 ESCs by crossing the floxed allele onto *Rosa26*-Cre-ERT2 and *Rosa26*-lox-stop-lox-YFP (see Materials and methods). Pregnant animals were used to isolate *Pou2f1^f1/fl^;Rosa26*-Cre-ERT2;*Rosa26*-lox-stop-lox-YFP ESC lines in which Oct1 could be acutely deleted and YFP induced by 4-hydroxytamoxifen (4-OHT) administration. Treatment of parent ESCs with 4-OHT resulted in variegated YFP^+^ colonies ([Figure 4A](#fig4){ref-type="fig"}, step one at top). Colonies with good morphology were picked (red arrow), trypsinized and expanded into derived ESC lines ([Figure 4A](#fig4){ref-type="fig"}, step two at bottom) that genotyped as *Pou2f1^Δ/Δ^* or *Pou2f1^fl/Δ^* ([Figure 4B](#fig4){ref-type="fig"}). The designation Δ will be used to differentiate this allele from the germline deficient allele used in [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"}. As with Oct1 germline-deficient ESCs, derived *Pou2f1^Δ/Δ^* ESC lines displayed normal colony morphology ([Figure 4C](#fig4){ref-type="fig"}), proliferated normally (not shown) yet expressed no Oct1 ([Figure 4D](#fig4){ref-type="fig"}). The derived cells showed normal karyotype profiles and could be propagated for \>1 month without loss of an undifferentiated phenotype (not shown). Similar to germline Oct1 deficient ESCs, derived *Pou2f1^Δ/Δ^* cells also expressed Oct4, Sox2 and Nanog at normal levels ([Figure 4D](#fig4){ref-type="fig"}).10.7554/eLife.20937.020Figure 4.Gene expression defects upon differentiation of Oct1 inducible-conditional ESCs.(**A**) YFP-epifluorescence and phase microscopy images of inducible-conditional ESCs. Top: parent *Pou2f1^fl/fl^* cells were treated with 500 nM 4-OHT for 24 hr. A colony with good morphology and variegated YFP expression was picked, trypsinzed, replated and expanded. Bottom: derived *Pou2f1^Δ/Δ^* ESCs. (**B**) PCR genotyping of parent (C2) and derived (13-1, 13-2) lines. Feeder fibroblasts were depleted by two serial 1 hr platings on plastic. The residual WT band in lane two is due to feeder contamination. The rightmost lane (lane 4) shows control tail DNA from a *Pou2f1^fl/+^* (top) or *Pou2f1^fl/Δ^* animal. (**C**) Epifluorescence and phase microscopy images of single colonies. Images were taken at the same magnification. (**D**) Immunoblots comparing lysates of vehicle-treated parent ESCs and derived KO cells. GAPDH is shown as a loading control. (**E**) Feeder-depleted ESCs were treated continuously with RA on gelatin-coated plates in the absence of LIF for 14 days. Media was changed every other day. cDNA was prepared every other day and used in RT-qPCR with primers against *Pou5f1* and *Sox2*. Averages of three biological replicates ±standard deviation are shown. Methodologically, the experiments were performed identically to [Figure 2A--B](#fig2){ref-type="fig"}. (**F**) Additional RT-qPCR using primers against the Oct4 target genes *Hoxa5*, *Hoxc6* and *Cdx2*. (**G**) *Pou2f1^Δ/Δ^* ESCs were differentiated into neurons as in [Figure 2C--G](#fig2){ref-type="fig"} by forming EBs for 8 days followed by 8 day in medium containing insulin, transferrin and selenium. Cells were fixed and used for immunofluorescence using DAPI and antibodies against YFP and β-tubulin III. (**H**) Immunofluorescence images were quantified based on arborized morphology. Approximately 700 total cells were analyzed. (**I**) Similar to (**G**) except parent *Pou2f1^fl/fl^*, ESCs were used and after 4 days in culture cells were treated with 500 nM 4-OHT for 24 hr to delete Oct1 and induce YFP. Two representative images are shown. (**J**) Immunofluorescence images were quantified based on YFP and β-tubulin III positivity. Percent total cells showing single or double staining, or percent β-tubulin III^+^ cells with and without YFP are shown. Approximately 700 total cells were analyzed.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.020](10.7554/eLife.20937.020)10.7554/eLife.20937.021Figure 4---figure supplement 1.Steady-state metabolite levels in parental WT and 4-OHT-treated *Pou2f1^Δ/Δ^* ESCs as determined by GC-MS.(**A**) Identified metabolites with total ion current (TIC) levels between 0.25 and 2.5. Normalization were achieved by setting the total ion current area under curve for all metabolites equal to each other. Average of four biological replicates is shown. Error bars depict ±standard deviation. (**B**) TICs between 1 and 15. \* denotes student T-test p\<0.05. (**C**) TICs between 10 and 200. (**D**) TICs between 100 and 1500.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.021](10.7554/eLife.20937.021)10.7554/eLife.20937.022Figure 4---figure supplement 2.Images of parental WT and 4-OHT-treated KO ESCs differentiating in the presence of RA.Left: phase microscopy images. Right: epifluorescence images taken using a YFP filter.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.022](10.7554/eLife.20937.022)

In differentiated cells, Oct1 promotes glycolysis and dampens mitochondrial function. Oct1 deficiency dramatically increases mitochondrial amino acid oxidation and oxygen consumption while decreasing glycolysis and to a lesser extent glucose oxidation ([@bib32]). These changes contribute to failure of fibroblasts to undergo oncogenic transformation, despite the fact that they grow at normal rates and can be immortalized by serial passage. To test if similar changes occur in ESCs lacking Oct1, we analyzed the metabolic profile of these cells. Few differences were noted, with only phosphoethanolamine (also known as phosphorylethanolamine, p=0.047) and inositol (p=0.037) showing significant changes ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The lack of difference may be due to redundant functions of co-expressed Oct4 and Oct6, or co-selection for metabolic stability when selecting and propagating ESCs.

Derived *Pou2f1^Δ/Δ^* ESC lines, and parent cell line controls, were subjected to RA-mediated differentiation. Similar to results using Oct1 germline-deficient ESCs, the derived *Pou2f1^Δ/Δ^* ESCs lost Oct4 and Sox2 expression with kinetics identical to the parent line ([Figure 4E](#fig4){ref-type="fig"}). Microscopic imaging of the differentiating cells revealed that they were morphologically similar until approximately d 12, at which point *Pou2f1^Δ/Δ^* cells showed an increase in columnar/epithelial appearance ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Also as before, the induction of silent, developmentally poised genes was defective: *Hoxa5* and *Hoxc6* both showed reduced expression in timecourse assays ([Figure 4F](#fig4){ref-type="fig"}). The cells also showed ectopic *Cdx2* expression upon RA treatment ([Figure 4F](#fig4){ref-type="fig"}). As with germline-deficient ESCs, *Pou2f1^Δ/Δ^* ESCs did not generate true neurons efficiently ([Figure 4G](#fig4){ref-type="fig"}).

To determine the effect of conditional Oct1 loss during differentiation, parent cells were treated with 4-OHT following 8 d EB formation and 4 d in insulin, transferrin and selenium. After an additional 4 days, cells were fixed and stained with antibodies against β-tubulin III to score neurogenesis and YFP to score deletion. 40--50% of the treated cells induced YFP. Nearly all cells that induced β-tubulin III and/or generated neuron morphology lacked YFP expression ([Figure 4I](#fig4){ref-type="fig"} and [Figure 4J](#fig4){ref-type="fig"}). A few cells (2/ \~ 700) were both YFP- and β-tubulin III-positive (not shown), though it is possible that these cells are *Pou2f1* heterozygous as 4-OHT treatment can result in recombination of only one allele ([Figure 4B](#fig4){ref-type="fig"}).

Oct1-deficient ESCs form smaller, less differentiated teratomas and fail to generate chimeric mice {#s2-3}
--------------------------------------------------------------------------------------------------

Parent and *Pou2f1^Δ/Δ^* ESCs were injected subcutaneously into contralateral flanks of NCr Nude immunocompromised animals to generate teratomas. ESCs lacking Oct1 consistently generated smaller tumors ([Figure 5A--C](#fig5){ref-type="fig"}). Immunoblotting confirmed that recovered tumors maintained their original Oct1 status ([Figure 5D](#fig5){ref-type="fig"}). Histological analysis confirmed that parent cells generated mature teratomas that included, e.g., glial tissue, and glandular epithelial and squamous elements ([Figure 5E](#fig5){ref-type="fig"}). In contrast, Oct1 deficient ESCs generated areas of focally immature cells, consistent with reduced differentiation. Occasionally tumors were comprised virtually entirely of primitive malignant cells resembling a germ cell tumor ([Figure 5E](#fig5){ref-type="fig"}, lower right).10.7554/eLife.20937.023Figure 5.Smaller, less differentiated teratomas and lack of contribution to adult mouse tissues in *Pou2f1^Δ/Δ^* ESCs.(**A**) 1 × 10^6^ ESCs were injected into flanks (left flank: control *Pou2f1^fl/fl^* parent cells, right flank: derived *Pou2f1^Δ/Δ^* ESCs) of NCr Nude mice. Images are shown at 4 weeks. (**B**) Images of dissected teratomas. Left side: white light. Scale in cm shown on the right. Right side: YFP fluorescence. (**C**) The mass from ten tumors was averaged and plotted. Error bars denote standard deviation. (**D**) Immunoblots are shown for Oct1 in lysates prepared from part of the individual teratomas. Lane 7: extracts from 293 T cells transiently over-expressing recombinant Oct1. α-Tubulin is shown as a loading control. The lack of α-Tubulin in lane seven arises from the fact that less protein was loaded due to high levels of recombinant Oct1. (**E**) H and E images of parent and KO teratomas. Top left: normal teratoma morphology comprised of mature elements, e.g glial tissue (arrowhead), mature squamous (left arrow) and ciliated glandular epithelial (right arrow). Top right: teratoma comprised predominantly of mature elements, but with immature elements (approximately 5% of the tumor, arrows). Bottom left: teratoma with both mature and immature elements represented. Mature squamous epithelium (right arrow) is abundant, while immature neuroepithelium (left arrow) is noted focally. Bottom right: tumor comprised almost entirely of a primitive malignant neoplasm that does not recapitulate any recognizable line of differentiation. Arranged in sheets and irregular nests, these cells exhibit marked cytologic atypia, with nuclear pleomorphism and coarsely-clumped chromatin. Nucleoli are variably prominent. Mitotic activity is brisk (arrows). (**F**) Parent ESCs (left side) or derived KO cells (right side) were injected into albino C57BL/6 blastocysts and implanted in pseudo-pregnant animals. Representative images are shown. (**G**) Average contribution is shown for the two cell types. ESCs contribution was assessed subjectively based on dark coat and eye color. 33 animals were tested in the case of the parent line and 36 animals were assessed in the case of the derived *Pou2f1^Δ/Δ^* line.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.023](10.7554/eLife.20937.023)10.7554/eLife.20937.024Figure 5---figure supplement 1.Pluripotent phenotype of ESCs immediately prior to blastocyst injection.Microscopy images of parental WT and two derived 4-OHT-treated, YFP-expressing, *Pou2f1^Δ/Δ^* ESC lines cultured in the absence of feeder fibroblasts. Images were taken by the University of Utah Transgenic Core Facility immediately prior to injection. An established WT eYFP-expressing ESC line (which fluoresces more brightly) is shown as a positive control.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.024](10.7554/eLife.20937.024)

A standard measure of pluripotency is the ability to contribute efficiently to adult cells and tissues ([@bib9]). We injected parent and *Pou2f1^Δ/Δ^* ESCs into albino C57BL/6 blastocysts, resulting in high contribution in the case of the parent line ([Figure 5F](#fig5){ref-type="fig"}, left), but no contribution in the case of the derived lines (right). The average percent chimerism from two separate sets of injections (33 animals from parent cell line injections, 36 combined from two different *Pou2f1^Δ/Δ^* lines) confirmed the lack of contribution ([Figure 5G](#fig5){ref-type="fig"}). 18/33 animals injected with parent ESCs showed some detectable chimerism (55%), while 1/36 animals injected with conditional knockout ESCs showed transient trace chimerism in the eye (0.03%). The cells were imaged immediately prior to blastocyst injection to confirm an undifferentiated phenotype ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

Defects in lineage-specific gene expression in differentiated Oct1-deficient ESCs {#s2-4}
---------------------------------------------------------------------------------

To identify gene expression changes stemming from loss of Oct1, we performed RNAseq with undifferentiated and 14 d RA-differentiated parent and *Pou2f1^Δ/Δ^* ESCs. Three independent replicates were performed for each of the four conditions. Between 18.1 and 24.9 million sequence reads were generated for each sample, 73% to 82% of which aligned uniquely to the mouse *Mm10* reference genome. 99.6% of the reads within coding regions aligned to the correct strand. Variance between replicates was similar regardless of genotype or differentiation state (not shown). Unsupervised hierarchical clustering indicated that 0 and 14 days samples separated clearly from each other regardless of genotype, while within each timepoint the KO and parent WT samples clustered together ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). These results indicated that the effect of RA treatment and differentiation on gene expression was far stronger than the effect of Oct1 deletion. Plotting gene expression levels in the parent vs *Pou2f1^Δ/Δ^* cells ([Figure 6A](#fig6){ref-type="fig"}) showed relatively few gene expression changes in the undifferentiated condition (\>2.5 fold, p\<0.01, 253 total genes). These genes never changed by \>7 fold ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). In contrast, 1123 genes change expression in differentiated *Pou2f1^Δ/Δ^* cells, some of which varied by \>200 fold. Plotting gene expression fold change vs. *p*-value ([Figure 6B](#fig6){ref-type="fig"}) recapitulated these findings. Comparing genes differentially expressed at the two timepoints revealed little overlap (23 genes, [Figure 6C](#fig6){ref-type="fig"}). Analysis of the genomic alignments revealed that expression of control genes such as *Tbp* was unaltered, while pluripotency genes such as *Nanog* were silenced equivalently ([Figure 6D](#fig6){ref-type="fig"}). Other pluripotency genes such as *Pou5f1*, *Klf4*, *Dnmt3l*, and *Dppa4* behaved similarly to *Nanog* (not shown). One gene showing increased expression in the undifferentiated state was *Pou2f3* (Oct11, [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). *Pou2f3* shows low but detectable mRNA expression in WT ESCs, and is repressed upon differentiation to nearly undetectable levels. It is slightly elevated in Oct1-deficient ESCs but decreases to an even greater extent upon differentiation. RT-qPCR confirmed these changes in the context of overall low expression ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). It is therefore unlikely that this protein provides a compensatory function upon differentiation.10.7554/eLife.20937.025Figure 6.Genome-wide changes in developmental gene expression following differentiation of Oct1 conditional-inducible deficient ESCs.(**A**) For each gene, averaged RNAseq FKPM (aligned Fragments Per Kilobase per Million aligned reads) values from three undifferentiated or 14-day RA-differentiated parent and KO ESCs were plotted on a log~10~ scale. Red genes signify significantly changed gene expression (Adj. p\<0.01, fold change \>2.5) at d 14. For each timepoint, genes showing \<50 total reads in both genotypes conditions were called unexpressed and are not displayed. (**B**) Volcano plots showing log~2~ averaged difference in gene expression vs. --10×log~10~ significance. Significantly altered genes (Adj. p\<0.01, 2.5-fold change) are shown in blue (down-regulated) or red (up-regulated). (**C**) Venn diagram showing total numbers of significantly (p\<0.01) differentially expressed (\>2.5 fold) genes in undifferentiated and 14-day RA-differentiated Oct1-deficient ESCs. Overlap shows genes differentially expressed at both timepoints. (**D**) Genome tracks of averaged RNAseq read densities (genome build mm10) for two control genes: *Tbp* (a constitutively expressed gene), and *Nanog* (expressed in pluripotent but not differentiated conditions). Arrows show directionality of gene transcription and size of the transcription unit. (**E**) Additional genome tracks are shown of three genes with poor induction in the KO condition: *Hoxa5*, *Hoxb9,* and *Nppa. Ahcy* is also shown, which becomes more strongly down-regulated in the differentiated condition. *Hoxa5* physically overlaps with *Hoxa3*, *Hoxaas3,* and *Hoxa6*, which are not highlighted. (**F**) Additional genome tracks are shown of genes showing ectopic expression in the differentiated condition: *Sox17*, *Cdx2*, *Pparg,* and *Plr8a6*. (**G**) RT-qPCR validations of additional genes identified by RNAseq, *Ahcy* and *Prl8a6. Tbp* is shown as a control. Average of three biological replicates ±standard deviation is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.025](10.7554/eLife.20937.025)10.7554/eLife.20937.026Figure 6---figure supplement 1.Differences in gene expression in differentiated Oct1 deficient cells revealed by RNAseq.(**A**) Heat map of gene expression differences across all biological replicates generated using unsupervised hierarchical clustering. 10,500 genes that vary at least fourfold across all samples were used. Color shows Log2 deviation of each gene from its average value across all the samples. Yellow= above average. Blue=below average. Each unit in the color key represents a doubling in intensity. Input values were log-scale FPKMs for each gene in each sample. (**B**) Genome tracks of *Pou2f3*. Asterisk: spurious background signal sometimes seen with poorly expressed genes. (**C**) RT-pPCR of *Pou2f3* expression. Average of three biological replicates ±standard deviation is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.026](10.7554/eLife.20937.026)10.7554/eLife.20937.027Figure 6---figure supplement 2.Differences in gene expression in differentiated Oct1 deficient cells revealed by RNAseq.(**A**) Genome tracks of additional genes showing decreased expression in the differentiated state identified by RNAseq. (**B**) Genome tracks of elevated genes.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.027](10.7554/eLife.20937.027)

Approximately 300 genes were induced poorly in RA treated *Pou2f1^Δ/Δ^* cells relative to normal controls. Many of these encode regulators of neuronal specification and differentiation. Examples include *Hoxa5*, *Hoxb9* and *Nppa* ([Figure 6E](#fig6){ref-type="fig"}). Other examples include *Foxg1*, *Pcdh17*, *Ptgfr*, *Akr1c18*, *Cts7*, *Duox2*, *Hoxc5*, *Hoxc6*, *Hoxc8*, *Hoxc10,* and *Dcx* ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). In addition, *Ahcy*, a stress-responsive Oct1 target ([@bib13]; [@bib33]) showed weakened expression in the absence of Oct1 specifically in the differentiated condition ([Figure 6E](#fig6){ref-type="fig"}). An even larger cohort of \~800 genes was aberrantly expressed upon differentiation of *Pou2f1^Δ/Δ^* cells. These genes are strongly associated with alternative developmental fates ([Figure 6F](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). Examples include *Sox17*, *Cdx2* and *Gata4* (endoderm), *Fgb* (endoderm/liver), *Gata2* (mesoderm/endothelial), *Pparg* and *Irx3* (mesoderm/mesenchymal), *Muc13* (epithelial/hematopoietic) and *Tnfrsf9* (which encodes CD137/hematopoietic). The difference in *Sox17* and *Gata2* expression between EBs (defective) and RA-differentiated cells (elevated) likely arises from the additional developmental fates specified in EBs.

Unexpectedly, differentiating *Pou2f1^Δ/Δ^* cells also resulted in inappropriate expression of genes associated with trophoblast and placental development, the specification of which is normally restricted to trophectoderm cells rather than the inner cell mass (from which ESCs are derived). Examples include *Cdx2* (which is also expressed in endoderm), *Prl8a6*, *Hand1* (which is also expressed in cardiomyocytes), *Pappa2*, *Prl3b1*, and *Psg27* ([Figure 6F](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). Some of these genes are also expressed in other lineages while others are highly specific. In aggregate, they indicate improper activation of an extra-embryonic program. Using RT-qPCR we confirmed unperturbed expression of *Tbp*, defective expression of *Ahcy*, and elevated expression of *Prl8a6* in differentiating Oct1-deficient ESCs ([Figure 6G](#fig6){ref-type="fig"}). These results indicate that Oct1 deficiency results in defective lineage specification upon differentiation.

We used ChIPseq to identify common and unique Oct1 and Oct4 target genes in ESCs. We also performed H3K4me3 ChIPseq as a control. The ChIPseq data were of high quality based on measures of signal/noise ratio (see Materials and methods). After filtering, 27.3 (Oct1), and 23.7 (Oct4) million alignable reads were generated, corresponding to 692 (Oct1), and 8673 (Oct4) peaks. Allocating the peaks to nearest genes revealed 209 unique Oct1 target genes, 356 common targets, and 5563 unique Oct4 targets ([Figure 7A](#fig7){ref-type="fig"}). The smaller size of the Oct1 target pool relative to Oct4 may be attributable to \>10 fold lower Oct1 levels in ESCs as observed by RT-qPCR ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1E](#fig1){ref-type="fig"}, [Figure 2A](#fig2){ref-type="fig"}) and RNAseq (not shown). Oct1 may also require a more open chromatin context, and/or the presence of specific co-bound factors, to access DNA. For example *Il2* and *Ifng* are known Oct1 targets in differentiated T cells ([@bib35], [@bib33]) but were not identified as targets in this analysis.10.7554/eLife.20937.028Figure 7.Unique and common Oct1 and Oct4 targets in ESCs.(**A**) Venn diagram illustrating Oct1 and Oct4 target gene profile and intersection with RNAseq gene set. (**B**) Motif analysis for peaks occupied uniquely by Oct1 or Oct4, and for peaks occupied by both proteins. Top shows best consensus sequences associated with binding. Bottom shows best matches to annotated weight matrices. In the case of known motifs, deviation of physiological binding sites from consensus causes recurring sequences meet threshold criteria for the compound 'Oct4-Sox2' site but not for a simple octamer site ('Oct4'). This is why the percentage of target sites computationally associated with 'Oct4-Sox2' is higher than for 'Oct4.' (**C**) Genome tracks showing ChIPseq enrichment for Oct1 (blue), Oct4 (gray) or H3K4me3 (red). Target gene and orientation is shown at the bottom of each track. *Pou5f1*, *Polr2a*, *Taf12* and *Pax6* are shown. (**D**) ChIP-qPCR validation of select ChIPseq targets. Fold enrichments using Oct1 and Oct4 antibodies at *Polr2a* and *Pou5f1* are shown. (**E**) RT-qPCR for three identified Oct1 target genes, *Tbx3*, *Tcf4* and *Tbx6* at 0, 2, 4,6, 8, 10, 12 and 14 d of differentiation. Expression was normalized to the control ribosomal gene RPL13. Three biological replicates were performed. Error bars denote ±standard deviation.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.028](10.7554/eLife.20937.028)10.7554/eLife.20937.029Figure 7---figure supplement 1.Oct1 and Oct4 ChIPseq read density at example co-bound genes.(**A**) Genome tracks of Oct1 and Oct4 enrichment at *Ell* in ESCs. (**B**) *Ahcy*. (**C**) *Rras2*.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.029](10.7554/eLife.20937.029)

Motif analysis of unique and co-bound peaks revealed significant differences in recognized DNA elements. Regions associated exclusively with Oct4 were significantly enriched for Oct-Sox compound elements that likely also associate with Sox2 in ESCs ([Figure 7B](#fig7){ref-type="fig"}). In contrast, target regions preferentially associated with Oct1 were enriched for the simple octamer element ATTTGCAT (shown by the software as an Oct4 motif in [Figure 7B](#fig7){ref-type="fig"}). Interestingly, co-occupied peaks strongly associate with a motif termed a MORE that is known to bind two Oct protein molecules ([@bib29]; [@bib43]). In differentiated cells lacking Oct4, oxidative stress induces homodimeric Oct1 binding to MORE-containing genes such as *Polr2a*, *Ahcy*, *Ell,* and *Rras2*. Oxidative stress-induced binding occurs via phosphorylation of a conserved serine residue in the DNA-binding domain ([@bib13]). These genes were constitutively co-bound by Oct1 and Oct4 in ESCs ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Additional examples of genes associated with Oct4 alone (*Pou5f1*), or Oct1 alone (*Taf12*) are shown in [Figure 7C](#fig7){ref-type="fig"}. This panel also shows another example of a MORE containing gene (*Polr2a*, two tandem MOREs binding four molecules) that also associates with both proteins but shows an Oct1 bias, as well as an example (*Pax6*) that is bound by both proteins but in two different locations. Using ChIP-qPCR we validated two genes, *Polr2a* (Oct1-enriched) and *Pou5f1* (Oct4-enriched, [Figure 7D](#fig7){ref-type="fig"}). The complete set of identified targets is shown in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}.

Intersecting the ChIPseq and RNAseq data revealed little overlap. Only 34 Oct1-bound or Oct1/Oct4 co-bound targets showed differential expression following RA-mediated differentiation ([Figure 7A](#fig7){ref-type="fig"}). Examples include *Pank4*, *Cdh5* and *Med16*. 193 Oct1-bound and 325 Oct1/Oct4-co-bound genes did not show expression differences at d 14. Examples include *Tbx3*, *Tcf4*, and *Txb6*, which also showed no differences throughout the differentiation timecourse ([Figure 7E](#fig7){ref-type="fig"}). Instead, 1066 genes with altered expression in differentiated Oct1-deficient cells showed Oct4 but not Oct1 enrichment. These findings indicate that (1) identified Oct1 targets were not differentially expressed upon differentiation, and (2) developmental genes shown to be differentially expressed in RA treated Oct1-deficient cells were not Oct1 targets in ESCs.

The above findings could be reconciled by postulating that (1) Oct functions at co-bound targets in ESCs to buffer them against oxidative stress as described previously in fibroblasts ([@bib13]; [@bib33]), and (2) developmental genes that are differentially expressed in Oct1-deficient cells but exclusively bound by Oct4 in ESCs become Oct1 targets during the differentiation process as Oct4 is lost. To test the first hypothesis, we studied the effect of H~2~O~2~ exposure on the expression of two co-bound genes, *Ahcy* and *Polr2a*, in ESCs ±Oct1. Both genes contain conserved MORE sequences ([Figure 8A](#fig8){ref-type="fig"}). Treatment of cells with 2 mM H~2~O~2~ resulted in a rapid loss of *Ahcy* and *Polr2a* mRNA specifically in Oct1-deficient ESCs ([Figure 8B](#fig8){ref-type="fig"}), exactly as observed in fibroblasts ([@bib13]; [@bib33]). As expected, these cells were hypersensitive to H~2~O~2~ ([Figure 8C](#fig8){ref-type="fig"}). These results suggest that as in other cell types, Oct1 functions in ESCs to buffer these genes from oxidative stress-associated inhibition.10.7554/eLife.20937.030Figure 8.Oct1/Oct4 co-binding to MOREs in ESCs, and inducible Oct1 binding to poised targets upon differentiation.(**A**) Conserved MOREs at two genes (*Ahcy* and *Polr2a*) co-bound by Oct1 and Oct4 in ESCs. The top co-bound de novo motif from [Figure 7B](#fig7){ref-type="fig"} is shown at top. The MORE sequence ([@bib29]; [@bib43]) is shown at bottom. Mammalian (mouse, human, dog) conservation is shown. MORE position relative to TSS is shown in parentheses. *Polr2a* contains two adjacent MOREs ([@bib13]), only one of which is shown here. (**B**) Parent and derived KO ESCs were treated with 2 mM H~2~O~2~ for the indicated times. *Ahcy* and *Polr2a* log~2~ mRNA levels were assessed by RT-qPCR. Three biological replicates were performed. Error bars denote ±standard deviation. (**C**) Microscopic images of the same cells during the treatment timecourse. (**D**) Conservation of the octamer sequence in the *Hoxc5* 3' UTR and *Rest*/*Nrsf* upstream region. Mammalian (mouse, human, dog) conservation is shown. Octamer element position relative to TSS is shown in parentheses. (**E**) Genome tracks showing ChIPseq enrichment at *Hoxc5*, *Rest* and upstream of *Myf5*, for Oct1 (blue), Oct4 (gray) or H3K4me3 (red). (**F**) ChIP-qPCR differentiation timecourse of four targets that exclusively bind Oct4 in ESCs. Fold enrichments using Oct1 and Oct4 antibodies at *Hoxc5*, *Pou5f1*, *Rest* and *Myf5* are shown. (**G**) Model for Oct1 and Oct4 function in ESCs and their differentiated progeny. The example of neuronal differentiation is shown. In stem cells, Oct1 and Oct4 collaborate at constitutively expressed MORE-containing targets such as *Polr2a* and *Ahcy* to insulate them against oxidative stress (red and black short dashed lines). Oct4 poises developmental genes of all embryonic lineages (long dashed black line) and repress trophectoderm-specific genes (solid black block line). Oct4 additionally activates pluripotency genes (solid black arrow). In differentiating cells, Oct1 occupies MORE genes in response to oxidative stress and buffers their expression, as described previously ([@bib13]; [@bib33]). Oct1 also contributes to eventual lineage-specific developmental gene activation (solid red line), and alternate developmental lineage gene repression (including trophectoderm, solid red block line).**DOI:** [http://dx.doi.org/10.7554/eLife.20937.030](10.7554/eLife.20937.030)

To test the hypothesis that Oct1 occupies Oct4 targets as cells differentiate and Oct4 is lost, we performed ChIP-qPCR timecourses using differentiating ESCs and antibodies against Oct1 and Oct4. Material was collected from 0, 2, 4, 6, 8, 10, 12 and 14 d of differentiation with RA. We chose a gene, *Hoxc5*, that contains a conserved perfect octamer sequence ([Figure 8D](#fig8){ref-type="fig"}), but is not an Oct1 target based on ChIPseq ([Figure 8E](#fig8){ref-type="fig"}). *Hoxc5* also shows poor induction in upon RA-mediated differentiation of *Pou2f1^Δ/Δ^* cells ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). Oct1 ChIP-qPCR revealed no binding in ESCs, as expected based on the ChIPseq ([Figure 8F](#fig8){ref-type="fig"}), however robust binding was transiently observed at 6 d. By 14 d of differentiation Oct1 binding was again undetectable. We also examined a target region between the linked *Myf5* and *Myf6* (*Mrf4*) loci on chromosome 10 that contains several near-perfect octamer sites (not shown), and is strongly bound by Oct4 but not Oct1 ([Figure 8E](#fig8){ref-type="fig"}). Oct1 inducibly occupied this region even more rapidly (2 d) as Oct4 binding was lost, and in this case Oct1 binding was maintained, at varying levels, during ESC differentiation ([Figure 8F](#fig8){ref-type="fig"}). Finally, we studied two additional genes, *Pou5f1* and *Rest* (Nrsf), which also contain conserved perfect octamer sequences in their regulatory regions and also show exclusive Oct4 binding. These genes are both expressed in ESCs and silenced as differentiation proceeds. Here early Oct1 binding was identified, which was maintained at low levels during the differentiation timecourse in the case of *Pou5f1* but transient in the case of *Rest* ([Figure 8F](#fig8){ref-type="fig"}). These results indicate a highly dynamic interplay between Oct1 and Oct4 in differentiating cells.

Discussion {#s3}
==========

Our results indicate that Oct1-deficient ESCs are unperturbed in terms of morphology, growth, metabolism, and gene expression. EBs formed from these cells are microscopically normal at early timepoints and express genes associated with all three germ layers. However, Oct1-deficient ESCs show phenotypic and molecular defects upon differentiation. These cells fail to form neurons and cardiomyocytes, generate smaller and less differentiated teratomas, and fail to contribute to adult mouse tissues. Prior work has shown that partial knockdown of Oct1 also inhibits neuron formation in the context of knockout of the related protein Oct2 ([@bib42]).

Three molecular defects manifest upon differentiation of Oct1-deficient ESCs. First, loss of Oct1 results in a failure to fully induce genes associated with a given developmental lineage. Second, Oct1 is necessary for the repression of alternative embryonic developmental lineages. As a result, upon differentiation gene expression programs are marked not only by poor induction of lineage-appropriate gene expression, but also by ectopic expression of genes specific to alternative lineages ([Figure 8G](#fig8){ref-type="fig"}). The third defect is mis-expression of genes associated with extra-embryonic lineages. These genes are normally under tight repression in ESCs and their differentiated progeny. For example, *Prl8a6* and *Prl3b1* are mis-expressed in RA-differentiated ESCs. Other genes such as *Cdx2* and *Hand1* are examples of genes expressed both in extra-embryonic and alternative embryonic lineages. For example, the *Cdx2* promoter contains a perfect consensus octamer element and is a known Oct1 target in somatic cells ([@bib12]; [@bib50]). In the early embryo, *Cdx2* promotes trophectoderm fate and is under tight repression by Oct4 ([@bib52]; [@bib53]). Later in development, *Cdx2* is induced in the endoderm-derived developing gastrointestinal tract ([@bib10]; [@bib18]) and during primitive hematopoiesis ([@bib49]), but is not widely expressed in ectoderm ([@bib37]). In RA-differentiated cells, *Cdx2* thus represents both a lineage-inappropriate gene and an extra-embryonic lineage. *Cdx2* is mis-expressed following RA-mediated differentiation of both germline and inducible-conditional Oct1-deficient ESCs. Interestingly Oct1 may execute the opposite function in extra-embryonic tissue, as germline Oct1-deficient mice show defects in extra-embryonic tissues including poor expression of *Cdx2* ([@bib31]).

ChIPseq experiments reveal that Oct1 and Oct4 regulate common and distinct targets in ESCs. These differences in bound targets lead to functional consequences, as the two proteins recruit different cofactors such as Jmjd1a in the case of Oct1 and Jmjd1c in the case of Oct4 ([@bib34], [@bib33]). Oct4 occupies a large group of \>5000 genes, including developmentally poised genes such as *Hoxc5* and *Myf5*, and core pluripotency genes such as *Pou5f1* and *Nanog*. Oct1 does not occupy these genes in ESCs, consistent with the ability of Oct1-deficient ESCs to maintain pluripotency. Instead Oct1 co-occupies a cohort of 325 genes with Oct4 that are highly enriched for a motif known as a MORE ([@bib29]; [@bib43]). Oct proteins are known to homo- and hetero-dimerize ([@bib13]; [@bib40]; [@bib43]; [@bib44]). The configuration of Oct proteins can determine cofactor association and hence regulatory output ([@bib29]; [@bib43]). Many of these constitutively co-bound genes were previously shown to become occupied by Oct1 upon oxidative stress exposure in differentiated cells lacking Oct4 ([@bib13]). The function of Oct1 at these genes is to insulate them against inhibition by oxidative stress. Fibroblasts lacking Oct1 show inappropriate repression of MORE-containing genes following H~2~O~2~ exposure ([@bib13]; [@bib33]). We demonstrate the identical phenotype using Oct1-deficient ESCs. Oct1 also exclusively associates with a small number (\~200) of other genes including *Taf12*, which contains another binding site variant known as a TMFORE ([@bib13]).

Notably, in undifferentiated cells Oct1 does not associate with developmental targets that become deregulated upon differentiation of Oct1-deficient ESCs. Oct4 is present at higher levels in ESCs compared to Oct1, suggesting that mass action may contribute to the lack of Oct1 binding. This model predicts that Oct1 would occupy these genes as Oct4 is lost during differentiation. We tested four regions bound by Oct4 but not Oct1 in ESCs, *Hoxc5*, *Myf5*/*Myf6*, *Rest* and *Pou5f1*, predicting that Oct1 binding will manifest as cells differentiate and Oct4 is lost. In all cases, Oct1 binding was observed at one or more points during the differentiation timecourse. We propose that Oct1 transiently replaces Oct4 at many such Oct4 target genes upon differentiation, where it promotes lineage-appropriate target gene expression, and represses expression of lineage-inappropriate targets. The binding events occur during a brief but important window during which critical decisions about suppression or potentiation of lineage-specific developmental Oct4 target genes are made. Binding also occurs before many of the affected target genes are induced, suggesting that Oct1 is not the principal driver of expression of these genes, but instead establishes a chromatin context in which these genes remain poised for expression, or become permanently repressed. Of the genes tested in ChIP-qPCR RA differentiation timecourses, the lineage-appropriate *Hoxc5* gene shows poor induction in upon differentiation of Oct1-deficient cells ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}), *Myf5* and *Myf6* are mesoderm-specific and lineage-inappropriate, *Rest* is both pluripotency-associated and lineage-inappropriate, and *Pou5f1* is more restricted to ESCs. These latter genes showed no evidence of ectopic expression. This observation can be reconciled with our model by positing that redundant mechanisms, perhaps mediated by other Oct proteins such as Oct6/Pou3f1, enforce their repression in differentiating ESCs.

The bipotential function of Oct1 is consistent with previous findings in fibroblasts and T cells ([@bib33]). Oct1 functions are mediated in part through association with the inhibitory chromatin remodeling complex NuRD ([@bib33]), or with Jmjd1a/KDM3A, a histone H3K9me2 lysine demethylase ([@bib35], [@bib33]). H3K9me2 also controls developmental gene induction ([@bib51]; [@bib54]) and reprogramming to pluripotency ([@bib8]; [@bib36]).

The ability of Oct1 to suppress genes for alternative developmental lineages is reminiscent of findings using T cells in which Oct1 suppresses alternative T cell lineage genes via inter-chromosomal communication between gene loci that execute opposing gene expression programs ([@bib15]). Oct1 interacts with CTCF ([@bib15]), helping it foster exclusive gene expression programs in T cells. More work is required to determine if Oct1 insures mutually exclusive embryonic developmental gene expression programs through similar mechanisms.

Materials and methods {#s4}
=====================

Derivation of Oct1 germline and conditional ESCs {#s4-1}
------------------------------------------------

All mice were C57BL/6J background. Oct1 germline-deficient ESCs were generated by intercrossing heterozygous *Pou2f1^-/+^* mice ([@bib47]) to generate a 1:2:1 ratio of *Pou2f1^-/-^: Pou2f1^-/+^: Pou2f1^+/+^* embryonic offspring. ESCs were derived from preimplantation blastocysts and genotyped. Heterozygous ESCs were not studied further. Littermate WT ESCs lines constituted the controls for these experiments. Oct1 inducible-conditional ESCs were generated by first separately crossing mice with the *Pou2f1* conditional (floxed) allele ([@bib35]) to the YFP reporter B6.129 × 1-*Gt(ROSA)26Sor^tm1(EYFP)Cos^*^/J^ (Jackson labs \#006148) and inducible cre transgenic line B6.129-*Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj^*^/J^ (Jackson labs \#008463). Resulting *Pou2f1^fl/fl^* animals were intercrossed to generate embryonic *Pou2f1^fl/fl^* offspring in which LSL-YFP was expressed from one *Rosa26* allele and Cre-ERT2 was expressed from the other. Parent ESCs were derived from these preimplantation blastocysts. The parent lines constituted the controls for derived 4-OHT-treated, *Pou2f1^Δ/Δ^*:YFP^+^ lines. Cell lines were routinely authenticated by genotyping. Mycoplasma testing was conducted regularly in-house using a previously published method ([@bib22]). Cells were negative throughout the study.

Cell culture {#s4-2}
------------

ESCs were cultured as previously ([@bib34]) with 2i conditions: the ERK inhibitor PD0325901 (1 μM, LC Laboratories) and the GSK3 inhibitor CHIR99021 (3 μM, LC Laboratories). 4-OHT (Sigma) was dissolved in ethanol and used at 500 nM for 24 hr. Two methods were used to generate EBs. Low-attachment dishes were used to generate WT and Oct1-deficient EBs for microscopic analysis, RT-qPCR and the generation of neurons. Briefly, ESCs were trypsinized and feeders depleted by binding to gelatin-coated dishes for 30--60 min. ESC suspensions were plated on low-attachment dishes for 5--7 days. For cardiomyocyte differentiation, the hanging drop method ([@bib48]) was used in order to generate single EBs in 96-well plates. Individual EBs were then used to generate cardiomyocyte colonies in 24-well plates. Generation of neurons was accomplished as in ([@bib3]), with modifications. Briefly, EBs were formed for 4 days using low-attachment dishes, followed by culture for a further 4 days as EBs in 0.1 μM RA/DMEM. After 8 days, EBs were trypsinized and cultured for 8 days in 1:1 F12:DMEM, 10 μg/mL insulin (SAFC Biosciences), 5.5 μg/mL transferrin and 38.7 μM sodium selenite (ThermoFisher) on laminin/poly-L-lysine-coated ChamberSlides (Corning). Cells in [Figure 2E--F](#fig2){ref-type="fig"} were cultured for eight additional d. For H~2~O~2~ treatment, ESCs were seeded 24 hr prior to treatment on 6-well plates with sparse feeders. Cells were treated with 2 mM H~2~O~2~ (Sigma) for the indicated times.

Immunoblotting {#s4-3}
--------------

Antibodies for immunoblotting were as follows: Oct4, Santa Cruz sc-5279; Oct1, Bethyl A301-716A + A301--171A; Nanog, GeneTex GTX100863; Sox2, GeneTex GTX101507; GAPDH, EMD Millipore, MAB374; α-Tubulin, Santa Cruz sc-5286.

RT-qPCR {#s4-4}
-------

RNA was isolated using TRIzol (Thermo Fisher, Waltham MA), followed by RNAeasy purification (Qiagen) using the RNA cleanup procedure. cDNA was synthesized using SuperScript III and random hexamers (Thermo Fisher). RT-qPCR oligonucleotide primers are listed in [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}.

Lentiviral Oct1 complementation {#s4-5}
-------------------------------

The *Oct1* (*Pou2f1*) cDNA and IRES (internal ribosomal entry site) elements were amplified and cloned together by overlap PCR. In the first PCR, primers to the 5' end of *Oct1* containing a *Not*I restriction site and to the 3' end of *Oct1* that contained a 5' extension of IRES-complementary DNA were used. The sequences were: Oct1-NotI-For: 5'-AATGAAAAAAGCGGCCGCCATGAATAATCCATCAGAAAC-3'; Oct1-Rev-IRES: 5'-TTAGGGGGGGGGGAGGGATCTTCACTGTGCCTTGGAG-3'. In the second PCR, an IRES sequence was amplified using primers to the 5' end of the IRES containing a 5' extension of DNA complementary of the *Oct1* 3' end, and primers to the 3' end of the IRES containing an *Nde*I restriction site. The sequences were: IRES-overlap-FOR: 5' AGATCCCTCCCCCCCCCCTAACGTTACTGGCCGAA-3'; IRES-Rev-NdeI: 5'- GGGAATTCCATATGTGTGGCCATATTATCATCGTGT-3'. The third PCR used as a template the PCR products from the first two rounds, along with the Oct1-NotI-For and IRES-Rev-NdeI primers. This process generated a DNA fragment containing an *Oct1* cDNA fused to an IRES at the 3' end, along with a *Not*I site at the 5' terminus and an *Nde*I site at the 3' terminus. The fragment was cloned into the optimized, self-inactivating, nonreplicative pHAGE lentiviral vector using the *Not*I and *Nde*I restriction sites. To insert a *Puro* cassette after the IRES, the cDNA was amplified using primers containing 5' *Nde*I and 3' *Cla*I restriction sites. The sequences were Puro-NdeI-For: 5'- GGAATTCCATATGATGACCGAGTACAAGCCCACGGT-3'; Puro-ClaI-Rev: 5' GGTTTATCGATTCAGGCACCGGGCTTGC-3'. Because the IRES apparently attenuated expression of the *Puro* resistance cassette in this vector, puromycin selection was performed at 0.75 μg/mL. To generate an empty vector control, the vector was cut with *Nde*I and *Not*I, filled in with Klenow fragment, and re-ligated.

Immunofluorescence {#s4-6}
------------------

Immunofluorescence was performed as described previously ([@bib14]), using mouse monoclonal antibodies against β-tubulin-III (R and D Systems MAB1195) and rabbit polyclonal antibodies against YFP (Life Technologies A6455). Secondary antibodies used were goat anti-rabbit-Alexa568 (Life Technologies A-11011) and goat anti-mouse-Alexa488 (Life Technologies A-11001).

Teratoma formation {#s4-7}
------------------

Teratomas were generated as described ([@bib24]) by injecting parent or KO ESCs into contralateral flanks of female NCr Nude mice (NCRNU-F, Taconic). Mice were sacrificed at four wk. Tumors were excised, washed with cold PBS and weighed. 1/3 of the excised tumor was used to make lysates for protein analysis using a Dounce homogenizer with RIPA lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.1% SDS, 0.1% sodium deoxycholate, 1 mM EDTA and protease inhibitors \[Roche\]) on ice. Lysates were centrifuged 10,000 × *g* for 10 min. Supernatant protein concentrations were normalized using Bradford assays. 6× Laemmli sample buffer was added. The mixture was boiled for 5 min and resolved using a 10% SDS-PAGE gel. The remainder of the tumor was fixed in formaldehyde, paraffin-embedded, sectioned and H and E stained for histological analysis by a blinded pathologist.

RNAseq {#s4-8}
------

RNA was prepared from three independent cultures of undifferentiated or 14 d RA-differentiated parent *Pou2f1^fl/fl^* or 4-OHT treated *Pou2f1^Δ/Δ^* ESCs. Concentration was determined using a Quant-iT RNA assay kit and a Qubit fluorometer (Thermo Fisher). Intact poly(A) RNA was purified from total RNA samples (100--500 ng) with oligo(dT) magnetic beads, and stranded mRNA sequencing libraries were prepared as described using the Illumina TruSeq mRNA library preparation kit. Purified libraries were qualified on an Agilent Technologies 2200 TapeStation using a D1000 ScreenTape assay. Molarity of adapter-modified molecules was defined by qPCR using the Kapa Biosystems Library Quant Kit. Individual libraries were normalized to 10 nM and equal volumes were pooled in preparation for Illumina sequencing. Sequencing libraries (25 pM) were chemically denatured and applied to an Illumina HiSeq v4 paired end flow cell using an Illumina cBot. Hybridized molecules were clonally amplified and annealed to sequencing primers with reagents from an Illumina HiSeq PE Cluster Kit v4-cBot. Following transfer of the flowcell to an Illumina HiSeq 2500 instrument (HCS v2.2.38 and RTA v1.18.61), a 125-cycle paired-end sequence run was performed using HiSeq SBS Kit v4 sequencing reagents. Fastq data quality were checked using Fastqc verision 0.10.1 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Quality scores dipped towards the 3' end of the reads, so reads were trimmed at 50 bases to eliminate poor-quality data. The resulting 50-base reads were aligned to the mouse mm10 genome (GRCm38, December 2011) plus splice junctions using novoalign version 2.08.01 (<http://www.novocraft.com>). Alignments to splice junctions were translated back to genome coordinates using the SamTranscriptomeParser application in the USeq package ([@bib26]). Aligned reads were quality checked using the Picard tools' CollectRnaSeqMetrics command (<https://broadinstitute.github.io/picard/>). On average 99.0% of the reads aligned to the mouse genome, with 78% of reads providing unique alignments, and 86% of reads providing alignments to protein coding and UTR regions of the genome. Tests for differential gene expression were performed with DESeq2, version 1.10.0 ([@bib17]). Genes with a count of at least 50 in one or more samples were tested. Genes showing at least 2.5-fold change of expression at an adjusted *p*-value of \<0.01 were selected as differentially expressed. Figures were generated in R version 3.2.3 (<http://www.r-project.org>) using functions from the gdata and gplots libraries.

ChIP/ChIPseq {#s4-9}
------------

ChIP was performed as described ([@bib34]). ChIP oligonucleotide primers are listed in [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}. Antibodies used were the following: Oct1 (Bethyl, a mixture of A301-716A + A301--717A), Oct4 (Santa Cruz, sc-8629) and H3K4me3 (Millipore, 07--473). ChIPseq was performed as described previously ([@bib34], [@bib35]), using a single IP per condition and clones of parent or derived Oct1-deficient ESCs. For ChIPseq, reads were aligned to the mouse reference genome (mm10) with the Burrows-Wheeler Aligner (BWA, version: 0.5.9). Reads were filtered for alignment quality of \>Q10 and duplicates were removed using Picard tools (function MarkDuplicates). After filtering there were 21.1 (H3K4me3), 27.3 (Oct1), and 23.7 (Oct4) million reads. MACSv2 peak caller (version: 2.1) was used to call ChIPseq regions of enrichment with the following parameters (-p 1e-5 \--nomodel \--shiftsize \<fragment_length/2\> for Oct1, Oct4 and -p 1e-2 \--broad for H3K4me3). To estimate the \--shiftsize parameter (predominant fragment length divided by 2) we performed strand cross-correlation analysis using SPP R package (version: 1.10.1) with default parameters. Peaks overlapping with ENCODE blacklisted regions were filtered using BEDtools (function itersectBed). We also discarded peaks localized to mitochondria, chromosome Y, and unmapped contigs. After filtering we had 692 (Oct1), and 8673 (Oct4) peaks. Signal to noise ratio was assessed by calculating normalized strand coefficient (NSC) and relative strand correlation (RSC) using the SPP R package with default parameters (version: 1.10.1). The obtained values of NSC and RSC (H3K4me3: 2.28, 1.25; Oct1: 1.02, 1.45; Oct4: 1.05, 2.32) indicate highly enriched datasets with large fragment-length peak as compared to read-length peak. The NSC value for Oct1 transcription factor was somewhat smaller but typical for high quality datasets generated for factors with small numbers of genuine binding sites (692 MACS2-identified peaks for Oct1). We used MACSv2 function bdgdiff to build fold-enrichment signal tracks for all positions in the genome. Signal tracks were converted to TDF files using igvtools (<https://www.broadinstitute.org/igv/>igvtools). Peaks were allocated to genes using the annotatePeaks.pl program from HOMER suite (Hypergeometric Optimization of Motif Enrichment, version: 4.7, <http://homer.salk.edu/homer/>) by determining the closest RefSeq transcription start sites of the genes to the peaks. Functional enrichment analysis was performed using the findGO.pl program from HOMER and Bonferroni as well as Benjamini and Hochberg correction for multiple testing corrections. Robustness of the analysis was confirmed using MEME-ChIP ([@bib19]), which generate highly similar motifs.

Motif analysis {#s4-10}
--------------

Transcription factor enrichment within ChIPSeq peaks (de novo motif discovery and known motif matching) was determined using findMotifsGenome.pl program from HOMER. Motif analysis was run on overlapped and separately on unique Oct1 and Oct4 ChIPseq peaks. Oct1 and Oct4 ChIPseq peak overlaps were defined by requiring the distance between peak summits to be ≤100 bp. Motif lengths of 6--24 bp were identified within 200 bp regions centered on peak summits and an option of random background was selected for motif discovery.
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The following dataset was generated:

Shen Z,Kang J,Shakya A,Tabaka M,Jarboe EA,Regev A,Tantin D,2017,Enforcement of developmental lineage specificity by transcription factor Oct1,<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85063>,Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE85063)
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Decision letter

Blackburn

Clare

Reviewing editor

MRC Centre for Regenerative Medicine, University of Edinburgh

,

United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Enforcement of developmental lineage specificity by transcription factor Oct1\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Fiona Watt as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript entitled: \"Enforcement of developmental lineage specificity by transcription factor Oct1\", Shen et al. have addressed the role of Oct1 in pluripotency and differentiation, by analysing the phenotype of Oct1 null ES cells via both conditional deletion in vitro and after deriving a null ES line. They show that the Oct1 null cells can be propagated under pluripotency conditions with no overt phenotypic differences from the parental line, but cannot undergo normal differentiation when challenged using multiple assays (differentiation to cardiomyocytes and neurons in vitro, and capacity to form teratomas and contribute to chimeras in vivo). Consistent with this, while pluripotency genes are down-regulated normally in the differentiation protocols, differentiation markers are expressed aberrantly. The authors then use RNAseq and ChIPseq (for Oct1, Oct4 and H3K4me3) to address the role of Oct1 during RA-induced ES differentiation. From this, they conclude that part of its effect is to insulate a set of target genes, co-bound by Oct4, from repressive effects of oxidative stress. They also reveal a dynamic interplay between Oct4 and Oct1 binding, where Oct1 takes over from Oct4 as Oct4 levels drop, and suggest this is required to promote lineage-appropriate and suppress lineage-inappropriate expression during differentiation. Overall, the findings are novel and interesting, and the manuscript is well presented. The reviewers have requested the following revisions, which should be addressed in the revised manuscript.

Essential revisions:

1\) We request that the authors distinguish between two possible explanations of their data, as detailed below: Oct1/Pou2f1 belongs to the POU family, in which the members share the POU domain as a DNA binding domain. Oct4/Pou5f1 is also a member of the POU family and known as a key transcription factor for establishment and maintenance of pluripotency. The authors have shown that Oct1 and Oct4 bind to mostly different targets in ES cells, although a small proportion of their target sites are shared, indicating their distinct role. Most of the genes occupied by Oct1 do not show differential expression during differentiation, suggesting that these are housekeeping genes. If the regulation of these housekeeping genes by Oct1is required for the survival of a set of differentiated cells, which may happen depending on particular metabolic states, the deficiency of Oct1 would eliminate these cells. Although the authors emphasized that the dysregulation of developmentally-regulated genes is responsible for the defect of differentiation of Oct1-null ES cells, it could alternatively be due to the elimination of the differentiated cells rather than the defect of differentiation event. RA-induced ES cell differentiation is quite a crude system for addressing this point. The authors are encouraged to apply a cleaner system of differentiation and to induce the conditional KO at intermediate states of differentiation event to distinguish these two possibilities.

2\) Related to this, the authors are requested to show whether the defects in expression of differentiation marker genes and misexpression of alternative marks shown in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} occurs equally across the whole population or only in a subset of cells. These are both possible interpretations of expression data taken from the whole population, but would could lead to different interpretations of the function and mechanism of Oct1 in controlling cell fate. The authors are also requested to clarify whether the defect in the formation of β-tubulin III-expressing neurons in the null versus wild-type cells shown in [Figure 2](#fig2){ref-type="fig"} corresponds to a failure to fully differentiate, or if the null cells are showing slower differentiation kinetics. Was this experiment continued beyond the normal time period of the differentiation protocol, and if so, did the null cells eventually \'catch up\' or did they genuinely fail to robustly produce the appropriate neurons?

3\) It was previously shown that Oct1-knockdown (\~ 50%) in ESCs does not result in any phenotype during neuronal differentiation because of functional redundancy with Oct2 (Theodorou et al. Genes & Dev. 2009. 23: 575-588). To address this inconsistency with their data, the authors are requested to carry out rescue experiments to make sure that Oct1 can rescue the differentiation capacity of Oct1 KO ES cells (e.g. with a constitutively-active Oct1 transgene), in order to confirm the Oct1-dependency of the phenotype.

4\) The authors are also requested to deal with the following queries related to data presentation or analysis:i) The authors have generated two germline Oct1 KO lines and littermate WT lines as well as two Oct1 inducible KO lines, however it is not clear whether they have carried out all their qPCR and RNA seq analysis from both lines and pooled together or they have just used one line. It is important to carry out all their experiments in both lines and plot them separately so one can see the variation between the different lines (same genotype) and that between the WT and KO.

ii\) The authors have not indicated how many biological replicates they have carried out for their ChIP-seq data. They are requested to clearly indicate the variation between the replicate libraries, which can then be pooled for later analysis.

iii\) The authors have only used one algorithm to carry out motif analysis, this analysis should be repeated using a different algorithm (such MEME-ChIP).

iv). Similarly, the authors should examine whether Oct2 can functionally compensate the loss Oct1 and rescue the differentiation phenotype of Oct1 KO ES cells.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Enforcement of developmental lineage specificity by transcription factor Oct1\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Fiona Watt (Senior Editor), a Reviewing Editor, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

As you will see from the reviewers' comments, there was a remaining concern regarding the interpretation of some of your data. In particular, the data presented in [Figure 4G-J](#fig4){ref-type="fig"} do not unequivocally demonstrate that switching from Oct4 to Oct1 is required for differentiation (as noted in the comments from reviewer 1). Therefore, we ask that you add Oct1 staining to the YFP staining presented and, in addition, that you address in the text the possible alternative explanations for these results (you might also consider changing the title in this light). If you do not feel able to make these changes, we would require the rescue experiment outlined by reviewer 1 to be included before the manuscript could be accepted for publication. We also request that you attend to both of the issues raised by reviewer 3, which can be dealt with by textual changes.

*Reviewer \#1:*

In the revised manuscript, the authors made several changes to address the points mentioned by the reviewers. The most important point the authors should confirm was the functional confirmation of the switching from Oct4 to Oct1 on induction of differentiation-associated genes to undergo proper differentiation event. Neuronal differentiation was well-established system and the combination of the inducible KO of Oct1 would allow them to give a clear answer to this question as the reviewers expected. However, the experiment performed by the authors was not well organized and the result was equivocal. If the switch from Oct4 to Oct1 at the beginning of differentiation event is functionally important, the constitutive KO ES cells will fail to give rise to terminally differentiated cells whereas the conditional KO induced after switching will differentiate, even in lower efficiency than WT ES cells. However, induction of KO event at day 4 of differentiation culture, the time point when Oct1 was already replace Oct4 at several target sites as shown in [Figure 8F](#fig8){ref-type="fig"}, completely abolished differentiation to mature neurons. This result suggested that Oct1 function is required for the late period of differentiation event or maintenance of the mature differentiated phenotype in cell-type-dependent manner. The assessment of KO event at cellular level was incomplete in this experiment. Why did the authors detect YFP expression, an indirect marker of inducible KO, rather than the loss of Oct1 protein with anti-Oct1 Ab?

An alternative way to address this point precisely is the rescue by the inducible Oct1 expression in Oct1-null ES cells after induction of differentiation. According to the answers to the reviewers\' comments, the authors tried to rescue Oct1-null ES cells by transfection of constitutively-active Oct1 transgene at different time point, and failed. Why not using the inducible expression system such as Tet-on system to drive Oct1 transgene? It is well-established system and commercially available.

The strict confirmation of this point is very important to support the hypothesis the authors proposed. Without such confirmation, the other data is insufficient to support the hypothesis. The role of Oct1 for normal proliferation, protection against stress, and maintenance of certain metabolic state in differentiated cell types would explain the defect of Oct1-null ES cells in chimera assay, teratoma assay and slower growth of EBs rather than the defect in differentiation event.

*Reviewer \#3:*

I think Tantin and colleagues have addressed most of the major concerns raised by the reviewers in the first round. After fixing few minor issues (see below), I would recommend the publication of this manuscript in *eLife*.

Issue 1: [Figure 6A and B](#fig6){ref-type="fig"}. The authors compare RNA-seq data of parental vs. KO in both undifferentiated and differentiated conditions. The authors conclude that the KO show more gene expression differences during differentiation. However, it is important to show variability across parental and KO samples separately in both conditions. i.e. one would expect that cells are more heterogeneous during RA-differentiation compared to pluripotency state. So, it is expected to see more difference in RA-differentiation state.

Issue 2: [Figure 7B](#fig7){ref-type="fig"} (bottom). the known Oct4-Sox2 motif was enriched in 22.9% of Oct4 unique peaks as compared to Oct4 motif which was enriched 15.3%. This does not make sense as Oct4 motif is the exact first half of the Oct4-Sox2 composite motif. One would expect Oct4 motif to be present in all Oct4-Sox2 (22.9%) sites plus few more sites that only contain Oct4 motif. The authors need to clarify what those percentages mean in the legend.

10.7554/eLife.20937.039

Author response

*Essential revisions:*

*1) We request that the authors distinguish between two possible explanations of their data, as detailed below: Oct1/Pou2f1 belongs to the POU family, in which the members share the POU domain as a DNA binding domain. Oct4/Pou5f1 is also a member of the POU family and known as a key transcription factor for establishment and maintenance of pluripotency. The authors have shown that Oct1 and Oct4 bind to mostly different targets in ES cells, although a small proportion of their target sites are shared, indicating their distinct role. Most of the genes occupied by Oct1 do not show differential expression during differentiation, suggesting that these are housekeeping genes. If the regulation of these housekeeping genes by Oct1is required for the survival of a set of differentiated cells, which may happen depending on particular metabolic states, the deficiency of Oct1 would eliminate these cells. Although the authors emphasized that the dysregulation of developmentally-regulated genes is responsible for the defect of differentiation of Oct1-null ES cells, it could alternatively be due to the elimination of the differentiated cells rather than the defect of differentiation event. RA-induced ES cell differentiation is quite a crude system for addressing this point. The authors are encouraged to apply a cleaner system of differentiation and to induce the conditional KO at intermediate states of differentiation event to distinguish these two possibilities.*

The short answer to this point is that we performed the experiment outlined by the reviewers ([Figure 4G-J](#fig4){ref-type="fig"}), who indicated that we differentiate inducible-conditional ESCs using a precise system (we chose neurons), exposing cells to tamoxifen at different time points. Neurons are generated by first differentiating ESCs into EBs in low-attachment plates, followed by subsequent plating in CultureSlide chambers with insulin, selenium and transferrin. Cells then grow out from the fragmented EBs and fill the chamber as a monolayer. Deletion of Oct1 by tamoxifen administration is inefficient ([Figure 4A-C](#fig4){ref-type="fig"}). Only a fraction of ESCs within colonies become YFP^+^, and not all of those delete both Oct1 alleles. Unlike in ESCs, where we can pick and characterize individual colonies, in differentiating neurons we do not know which yellow cells have deleted one vs. both Oct1 alleles, and so we have to rely on the power of numbers. We treated differentiating cells with 4-OHT at different points during EB formation and subsequent differentiation of neurons. Deletion in EBs was highly inefficient. At only one timepoint (4 days after plating in chambers, 12 days into differentiation) did we generate YFP-positivity at an efficiency (40-50%) that allowed us to conduct this experiment. We fixed the neurons at endpoint and performed immunofluorescence with antibodies against YFP (red) and β-III-tubulin (green). We observe a much smaller fraction of YFP^+^ cells that express β-III-tubulin, and an even smaller fraction of YFP^+^ cells that form true arborized neurons (2 out of \~750 cells analyzed). These few cells are likely to be Oct1 heterozygous, though it is not possible to prove this. Representative images and quantified data from these results are now shown in [Figure 4I-J](#fig4){ref-type="fig"}. For completeness, we also now show the effect of conditional Oct1 deletion in ESCs on neuron formation. The effect is identical to that seen in germline-deficient ESCs, as expected ([Figure 4G-H](#fig4){ref-type="fig"}).

Regarding the larger reviewer rationale behind this experiment (that cells might be dying and skewing populations): we and others have shown that although it binds and regulates housekeeping genes Oct1 is not a housekeeping factor. Oct1 is dispensable for cell viability. Oct1 loss, either by knockout or RNAi) does not impede proliferation rates in standard culture conditions such as we use here. Published examples include primary MEFs, A549 and MD-MBA-231 cell lines, fetal liver blood progenitors, developing and activated primary T cells, total B cells and macrophages. Submitted work using CRISPR shows the same result in primary MEFs and MCF-7 cells. In unpublished work, deletion in the gut retains normal architecture and homeostasis, maintaining deletion for \>100 days. Instead Oct1 loss specifically impairs regeneration following epithelial cell damage. The ratio of oxidative to glycolytic metabolism in these situations is changed as expected, but in rich media and without some form of stress, cells are surprisingly resilient to such metabolic alterations. In our EB, cardiomyocyte, true neuron and RA/neuronal differentiation experiments, we note no differences in cell death (e.g., Supp. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, Figure 2---figure supplement 2 and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Finally, work from others shows that germline Oct1 null embryos, in which lethality due to trophoblast defects is circumvented with tetraploid complementation, do not die until E9.5, which seems incompatible with a model that has large populations of embryonic cells dying upon implantation and initial specification/differentiation.

*2) Related to this, the authors are requested to show whether the defects in expression of differentiation marker genes and misexpression of alternative marks shown in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} occurs equally across the whole population or only in a subset of cells. These are both possible interpretations of expression data taken from the whole population, but would could lead to different interpretations of the function and mechanism of Oct1 in controlling cell fate. The authors are also requested to clarify whether the defect in the formation of β-tubulin III-expressing neurons in the null versus wild-type cells shown in [Figure 2](#fig2){ref-type="fig"} corresponds to a failure to fully differentiate, or if the null cells are showing slower differentiation kinetics. Was this experiment continued beyond the normal time period of the differentiation protocol, and if so, did the null cells eventually \'catch up\' or did they genuinely fail to robustly produce the appropriate neurons?*

There are two points here, both of which are valid. The first is whether the defects observed with Oct1 loss are partial in nature across many cells, or whether a much smaller fraction of cells differentiate completely normally. The data in [Figure 2C](#fig2){ref-type="fig"} already provides a sense of this: in the neuron differentiation cultures we can find multiple examples of Oct1 deficient cells with poor β-III-tubulin staining, but nevertheless show staining above background. Rarely however we do see positive cells that have a neuronal appearance (as quantified in panels 2D, 4H and 4J, though 4J may be quantifying heterozygotes). To illustrate this better, we now show new images with quantifications ([Figure 2C-D](#fig2){ref-type="fig"}). Therefore, in the absence of Oct1 we observe many more Oct1 deficient cells with poor/incomplete differentiation, at least based on β-III-tubulin staining and arborization as criteria. Regarding the second, kinetic, question, the data in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} shows that even early during differentiation into EBs, abnormal β-III-tubulin staining is evident in the differentiating knockout cells. To further address this comment, we fixed and stained germline Oct1-deficient ESCs that had been differentiated into neurons for longer periods. We again used the terminal differentiation marker β-III-tubulin. At no point do Oct1 deficient cells "catch up", indicating that the defects observed with Oct1 deficiency are not due to changes in kinetics. Data from 8 day-extended cultures are shown in [Figure 2E-F](#fig2){ref-type="fig"}. We reference the 16 day-extended culture results as data not shown.

*3) It was previously shown that Oct1-knockdown (\~ 50%) in ESCs does not result in any phenotype during neuronal differentiation because of functional redundancy with Oct2 (Theodorou et al. Genes & Dev. 2009. 23: 575-588). To address this inconsistency with their data, the authors are requested to carry out rescue experiments to make sure that Oct1 can rescue the differentiation capacity of Oct1 KO ES cells (e.g. with a constitutively-active Oct1 transgene), in order to confirm the Oct1-dependency of the phenotype.*

We added language to the Discussion section acknowledging the above study, which shows that partial Oct1 knockdown reduces neuron formation in the context of an Oct2 knockout. It is not clear there is any inconsistency here, given that the knockdown in the prior study was only 50%, and given that transient transfection of siRNAs was used. Oct1 germline null heterozygotes are viable and fertile, suggesting that a 50% reduction is insufficient for the phenotypes we describe here to manifest. Additionally, we use multiple cell lines derived using two different methods (germline Oct1-deficient ESCs and WT lines derived in parallel, and conditional-inducible knockout ESCs in which Oct1 is deleted and tested compared to matched vehicle-treated parental controls). Both methods arrive at the exact same conclusions. We did attempt additional experiments to address this point. The language is not clear but generating a mouse transgene was not feasible for this study. As an alternative, we used the RA differentiation paradigm with MSCV viral transduction of a vector construct encoding Oct1 and a puromycin resistance cassette. We attempted viral transductions at nearly every day of RA differentiation. We attempted multiple infections of concentrated virus. Nonetheless infection rates were \<10%, possibly because there is not much cell division at any given time point, and the results were uninterpretable. It would be possible to circumvent this issue by sub-cloning the mouse Oct1 cDNA into a lentiviral vector, however even this approach has caveats. For example, Oct1 levels fluctuate during differentiation ([Figure 2A](#fig2){ref-type="fig"}) and it is not clear if constitutive expression from a viral promoter constitutes "rescue." The relative levels of Oct1 and Oct4 clearly have effects on gene occupancy, and it is likely that similar mass-action effects occur with Oct1, Oct2, Oct6 and other neuronal Oct binding transcription factors. It is also not clear whether the cells remaining after infection and selection are similar in composition to un-manipulated RA-differentiated cells, although empty vector controls partially address this. Lastly, the timing of the infection may be important, so one could try to complement Oct1 at day 2, 4, 6, 8, 10, 12 or 14. For all these reasons it would take many additional months to carry through with such an experiment, with a high potential for uninterpretable results.

*4) The authors are also requested to deal with the following queries related to data presentation or analysis:i) The authors have generated two germline Oct1 KO lines and littermate WT lines as well as two Oct1 inducible KO lines, however it is not clear whether they have carried out all their qPCR and RNA seq analysis from both lines and pooled together or they have just used one line. It is important to carry out all their experiments in both lines and plot them separately so one can see the variation between the different lines (same genotype) and that between the WT and KO.*

We did not mix lines, but did confirm the phenotypes shown with multiple lines. We have clarified in the manuscript text that data are shown for a single example of either germline or conditional KO and controls, rather than pooling different lines. We anticipated this concern in the manuscript, which is why we also generated inducible-conditional ESCs and tested knockout in these lines compared to the vehicle-treated parent line.

*ii) The authors have not indicated how many biological replicates they have carried out for their ChIP-seq data. They are requested to clearly indicate the variation between the replicate libraries, which can then be pooled for later analysis.*

We have clarified the text that ChIPseq libraries were prepared exactly as in Shakya et al. MCB 2015 and Shakya et a JEM 2015, using a single a IP per condition, from single clones of parent or matched derived Oct1 deficient ESCs. The ChIP material was first validated using *Pou5f1* for Oct4 and *Polr2a* for Oct1. H3K4me3 was used as an internal quality control. All ChIP-qPCR in the manuscript uses at least three experimental replicates, and these results substantiate the ChIPseq. Analysis of the DNA sequences within the ChIPseq peaks robustly identifies octamer DNA binding sites for both Oct1 and Oct4, and specific octamer variants for sites co-bound by both proteins (below). We recognize that this is not ideal, but because a large number of reads is required in order to validate each experimental condition, splitting the cells three ways, then performing ChIP and sequencing separately, then combining again, increases expense without a commensurate increase in the likelihood of generating meaningful data.

*iii) The authors have only used one algorithm to carry out motif analysis, this analysis should be repeated using a different algorithm (such MEME-ChIP).*

We performed the same analysis using MEME-ChIP. The top motifs found by both software packages are nearly identical, with similarly strong E-values for MEME-ChIP (HOMER uses P-values). This result confirms that our ChIPseq and analysis were robust (see the point above). We now state this in the manuscript text, though did not think the results were relevant enough to be included (they can be derived from our data and we can provide them on request). Of import here, both algorithms identify MOREs as the top sequence simultaneously occupied by Oct1 and Oct4. MOREs are known to bind Oct protein dimers in a novel configuration, and we had previously identified inducible Oct1 occupancy of MOREs following oxidative stress exposure in differentiated cells (PMID: 19171782). In the future, we hope to determine how Oct1 and Oct4 constitutively occupy sites that are inducibly occupied by Oct1 following stress in cells lacking Oct4.

*iv) Similarly, the authors should examine whether Oct2 can functionally compensate the loss Oct1 and rescue the differentiation phenotype of Oct1 KO ES cells.*

We have not studied Oct2 (and Oct6, and Oct11), both in order to make the manuscript straightforward and due to financial constraints. Whether or not Oct2 complements certain gene expression phenotypes is an interesting question, but regardless of the outcome would not alter any of the fundamental conclusions in the current study. We therefore maintain that such experiments are more appropriate for a future study.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:*

*As you will see from the reviewers' comments, there was a remaining concern regarding the interpretation of some of your data. In particular, the data presented in [Figure 4G-J](#fig4){ref-type="fig"} do not unequivocally demonstrate that switching from Oct4 to Oct1 is required for differentiation (as noted in the comments from reviewer 1). Therefore, we ask that you add Oct1 staining to the YFP staining presented and, in addition, that you address in the text the possible alternative explanations for these results (you might also consider changing the title in this light). If you do not feel able to make these changes, we would require the rescue experiment outlined by reviewer 1 to be included before the manuscript could be accepted for publication. We also request that you attend to both of the issues raised by reviewer 3, which can be dealt with by textual changes.*

The short answer to this is that we performed the rescue experiment, for which we show results with *Hoxa5* (new [Figure 2C-D](#fig2){ref-type="fig"}). For technical reasons Oct1 and β-III-tubulin co-staining cannot be performed and generate satisfying results. This is why we used YFP, and one of the reasons why we engineered the LSL-YFP reporter cassette into the ESCs. The long explanation: Our results in the first resubmission show that tamoxifen treatment and Cre induction significantly diminishes formation of true neurons ([Figure 4G-J](#fig4){ref-type="fig"}). We can interpret this as Oct1 deletion because of the robustness of the effects. If we had not observed strong differences, then the need to corroborate the YFP induction as reading out Oct1 deletion would have been more important. Nevertheless, we tried and failed to perform Oct1/β-III-tubulin co-staining, as outlined below. Because we knew that it would be a lingering issue, we then sub-cloned Oct1 into a lentiviral vector with a puromycin resistance cassette and infected differentiating Oct1-deficient ESCs. We chose to use RA-mediated differentiation, both because we have a clearer understanding of gene expression, and because at \~3 weeks these experiments take half as long compared to those using formation of true neurons. After several rounds of experiments, we now know that infection and selection with empty vectors at most differentiation timepoints, particularly late timepoints, changes expression of developmental targets genes such as *Hoxa5* and *Cdx2*. This confirms our initial concern, raised in the prior round of review, that selection skews the populations of cells remaining on the plate. However empty vector infection on day 4-5 (we performed two rounds of infection), generated minimal gene expression changes, at least on an averaged population level. This suggests, but does not prove, that population skewing by lentiviral infection is minimal at this time point. Subsequent experiments using vectors containing Oct1 shows that infection and selection infection significantly augments *Hoxa5* expression, complementing Oct1 loss. We hope these findings now address the reviewer's remaining issues.

We are willing to change the title should it be deemed necessary. One possibility, more observational and less interpretive, would be "Transcription factor Oct1 both ensures robust expression of lineage- appropriate developmental genes, and represses expression of lineage-inappropriate genes, in differentiating ESCs."

*Reviewer \#1:*

*In the revised manuscript, the authors made several changes to address the points mentioned by the reviewers. The most important point the authors should confirm was the functional confirmation of the switching from Oct4 to Oct1 on induction of differentiation-associated genes to undergo proper differentiation event. Neuronal differentiation was well-established system and the combination of the inducible KO of Oct1 would allow them to give a clear answer to this question as the reviewers expected. However, the experiment performed by the authors was not well organized and the result was equivocal. If the switch from Oct4 to Oct1 at the beginning of differentiation event is functionally important, the constitutive KO ES cells will fail to give rise to terminally differentiated cells whereas the conditional KO induced after switching will differentiate, even in lower efficiency than WT ES cells. However, induction of KO event at day 4 of differentiation culture, the time point when Oct1 was already replace Oct4 at several target sites as shown in [Figure 8F](#fig8){ref-type="fig"}, completely abolished differentiation to mature neurons. This result suggested that Oct1 function is required for the late period of differentiation event or maintenance of the mature differentiated phenotype in cell-type-dependent manner. The assessment of KO event at cellular level was incomplete in this experiment. Why did the authors detect YFP expression, an indirect marker of inducible KO, rather than the loss of Oct1 protein with anti-Oct1 Ab?*

*An alternative way to address this point precisely is the rescue by the inducible Oct1 expression in Oct1-null ES cells after induction of differentiation. According to the answers to the reviewers\' comments, the authors tried to rescue Oct1-null ES cells by transfection of constitutively-active Oct1 transgene at different time point, and failed. Why not using the inducible expression system such as Tet-on system to drive Oct1 transgene? It is well-established system and commercially available.*

*The strict confirmation of this point is very important to support the hypothesis the authors proposed. Without such confirmation, the other data is insufficient to support the hypothesis. The role of Oct1 for normal proliferation, protection against stress, and maintenance of certain metabolic state in differentiated cell types would explain the defect of Oct1-null ES cells in chimera assay, teratoma assay and slower growth of EBs rather than the defect in differentiation event.*

There is no reason why Oct1 cannot both replace Oct4 at certain genes early in differentiation, and also continue to be required other aspects and fate transitions later in development. The reviewer is equating the ChIP timecourse result using RA differentiation culture in [Figure 8F](#fig8){ref-type="fig"} with 4-OHT treatment after 8 days of EB formation, followed by 4 days culture in chamber slides with neuron differentiation medium in [Figure 4I-J](#fig4){ref-type="fig"}. Binding of Oct1 to target genes in these two assays systems can't be equated.

We used 4-OHT at the only point at which deletion was efficient. The reason we used YFP instead of Oct1 for immunofluorescence is 1) the YFP antibody is superior to the Oct1 antibody for IF, 2) the Oct1 and β-III-tubulin antibodies are both rabbit polyclonal (we circumvented this by purchasing additional antibodies), 3) the staining protocols for Oct1 and β-III-tubulin are incompatible, relying on formaldehyde vs. methanol fixation, and no mutually compatible protocol could be found. But most importantly, we obtained the positive result that Oct1 inducible-conditional cells exposed to Cre recombinase 12 days after differentiation (4 days in chamber slides) fail to form neurons efficiently ([Figure 4G-J](#fig4){ref-type="fig"}). The YFP staining would have been a significant issue of there had been no or small differences, in which case the possibility of heterozygous deletion and remaining Oct1 protein could be raised and a follow-up Oct1 stain would have been critical.

To further address this reviewer, we sub-cloned Oct1 into a lentiviral vector, providing us the opportunity to infect post-mitotic cells. As outlined in the response to the first round of reviewer comments, there are multiple factors that make this experiment non-ideal. Two are the fact that an infected and selected population of cells may not recapitulate the original population, due to preferences in the cell types or growth states infected, and the fact that Oct1 levels modulate significantly during differentiation and expression from a viral LTR may not recapitulate this complex regulation. The latter becomes a significant issue in light of the findings from the manuscript that relative levels of Oct1 and Oct4 (and presumably other Oct proteins) is a significant controller of gene occupancy and regulation. We infected RA-differentiating cultures of germline Oct1-deficient ESCs with lentiviruses encoding Oct1 (or empty vector) at multiple timepoints during differentiation, selected with puromycin, and tested gene expression by RT-qPCR. At most of these times, especially late in differentiation, infection and selection with empty vector was sufficient to skew expression of test genes such as *Hoxa5* and *Cdx2* (now shown). This result strongly suggests that infection and selection at these time points skews the population of cells under study. We therefore focused on one time at which gene expression changes caused by empty vector infection were minimal: day 4 and 5 of differentiation. We infect the cells twice to maximize efficiency, and apply puromycin selection 24 hr after the second infection throughout the remainder of the 14-day timecourse. After differentiation we collected RNA, prepared cDNA and tested gene expression. We confirmed that Oct1 was over- expressed in 293T cells transfected with Oct1-encoding vectors but not empty vector controls at the protein level ([Figure 2H](#fig2){ref-type="fig"}) and in the RA cultures infected with lentivirus at the mRNA level (not shown).

We focused on *Hoxa5*, which is inappropriately repressed upon RA-mediated differentiation of Oct1 deficient ESCs. Infection of differentiating Oct1 deficient ESCs using constructs expressing Oct1 increased *Hoxa5* expression ([Figure 2I](#fig2){ref-type="fig"}). These results suggest that complementing with Oct1, at least at this timepoint, restores at least some gene expression. We have added to the text, figure legends and Methods sections to incorporate these findings.

*Reviewer \#3:*

*Issue 1: [Figure 6A and B](#fig6){ref-type="fig"}. The authors compare RNA-seq data of parental vs. KO in both undifferentiated and differentiated conditions. The authors conclude that the KO show more gene expression differences during differentiation. However, it is important to show variability across parental and KO samples separately in both conditions. i.e. one would expect that cells are more heterogeneous during RA-differentiation compared to pluripotency state. So, it is expected to see more difference in RA-differentiation state.*

We appreciate the reviewer's enthusiasm about the work. Although RA-differentiated cells are more heterogenous than undifferentiated ESCs, the variance in gene expression in the population of cells between RNAseq replicates is not. If it were, the *P*-values would not be robust and [Figure 6B](#fig6){ref-type="fig"} would not show differences on the Y-axis. To further solidify this, we are attaching a Pearson correlation of the RNAseq raw expression count data for all genes ([Author response images 1](#fig9){ref-type="fig"} and [2](#fig10){ref-type="fig"}). These figures recapitulates the finding that the differences in gene expression in differentiated vs. pluripotent are stronger than differences due to inducible knockout. Relevant here, replicate variance (as groups of nine squares) are all high at \~.99 regardless of the condition. We have modified the text to state that the findings in [Figure 6](#fig6){ref-type="fig"} and associated figure supplements are not due to increased variance in the differentiated condition.10.7554/eLife.20937.034Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.034](10.7554/eLife.20937.034)10.7554/eLife.20937.035Author response image 2.**DOI:** [http://dx.doi.org/10.7554/eLife.20937.035](10.7554/eLife.20937.035)

*Issue 2: [Figure 7B](#fig7){ref-type="fig"} (bottom). the known Oct4-Sox2 motif was enriched in 22.9% of Oct4 unique peaks as compared to Oct4 motif which was enriched 15.3%. this does not make sense as Oct4 motif is the exact first half of the Oct4-Sox2 composite motif. One would expect Oct4 motif to be present in all Oct4-Sox2 (22.9%) sites plus few more sites that only contain Oct4 motif. The authors need to clarify what those percentages mean in the legend.*

For identification of known motifs, both HOMER and CentriMo (MEME suite) assign a given sequence to the strongest weight matrices based in statistical power, which is stronger for longer motifs. We ran multiple simulations using synthetic and physiological sequences. With consensus Oct:Sox motifs the number of tested targets with recognized Oct4 and Oct4-*Sox2* motifs is the same. However, physiological transcription factor binding sites can deviate from consensus, especially in the case of longer sequences. Sequence mismatches lower the relative enrichment of the Oct4 motif as compared to Oct4-*Sox2*. Therefore, the presence of non-consensus but physiological sequences causes the composite motifs to score higher and, for a given threshold value, are reported by motif-finding software at a higher percentage as compared to an individual motif. We have added to the legend for this panel concisely explaining the percentages.
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